Design and development of drug delivery systems for immediate and sustained release utilizing hot melt extrusion by Singh, Abhilasha
University of Mississippi 
eGrove 
Electronic Theses and Dissertations Graduate School 
1-1-2012 
Design and development of drug delivery systems for immediate 
and sustained release utilizing hot melt extrusion 
Abhilasha Singh 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/etd 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Singh, Abhilasha, "Design and development of drug delivery systems for immediate and sustained release 
utilizing hot melt extrusion" (2012). Electronic Theses and Dissertations. 1486. 
https://egrove.olemiss.edu/etd/1486 
This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
DESIGN AND DEVELOPMENT OF DRUG DELIVERY SYSTEMS FOR IMMEDIATE AND 
SUSTAINED RELEASE UTILIZING HOT MELT EXTRUSION TECHNIQUES 
 
 
 
 
A Dissertation  
presented for the Doctor of Philosophy degree in the Department of Pharmaceutics 
The University of Mississippi 
 
 
 
Abhilasha Singh 
July 30
 th
 2011 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright Abhilasha Singh 2012 
ALL RIGHTS RESERVED 
ii 
 
ABSTRACT 
Polymers have indispensable role in pharmaceutical formulation development. Polymer 
choice is a critical factor to obtain the desired drug-release profile during formulation 
development for HME (Hot melt extrusion). Many commercially available, pharmaceutical-
grade polymers can be used in HME formulations. The suitable polymer choice facilitates 
processing in the extruder. When choosing a polymer to use in a formulation, processing 
conditions and processing attributes of the active pharmaceutical ingredients (APIs) should be 
considered. The physicochemical and the mechanisms of drug release from drug delivery 
systems prepared by utilizing HME with various polymeric carriers were investigated. 
Amorphous forms of API can have as much as 10-1600 fold higher solubility than their 
crystalline forms. HME technology is extensively been used to convert crystalline form to 
amorphous form of drug with increased solubility with polymeric matrices as carriers. Efavirenz 
(EFZ) and Carbamazepine (CBZ) are crystalline lipophilic model drugs used in the studies. 
These are class II drugs (low solubility, high permeability) according to the BCS guidance by the 
FDA.  
Various polymers for example cellulose ethers (HEC, HPC and HPMC), hypermellose ester 
derivatives (HPMCAS and HPMCP) and acrylic polymer (Eudragit
®
 EPO) with pH dependant 
solubility were examined for suitability as solubility enhancers for EFZ and processability in 
melt extrusion processes. To determine suitable polymeric carrier, different tools like solubility 
parameter calculation, Thermogravimetric analysis (TGA), Differential scanning calorimetry 
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(DSC) and Dissolution were employed. The physicochemical characteristics of the extruded 
formulations were compared to the respective physical mixtures to examine the effect of the 
extrusion process. Furthermore, HME formulations were evaluated for drug polymer interaction 
utilizing Fourier transform infrared spectroscopy (FTIR). 
Sugar alcohols were used as carriers in solid dispersions, since it is known that glass formation is 
common in many polyhydroxy substances, presumably due to their strong hydrogen bonding 
which may prevent re-crystallization of the amorphous form of drug molecules. Furthermore, 
they possess the advantage of high thermal stability and absence of browning reactions. The 
sugar alcohols (Mannitol, Sorbitol, and Xylitol) investigated in this study proved to be very 
effective in forming solid dispersions and enhancing solubility of CBZ form III. Xylitol 
exhibited good processability. 
Chlorpheniramine Maleate (CLPM) and Diltiazem Hydrochloride (DTZ) were used as a model 
API to design a sustained release pellet formulations utilizing Ethocel™ (EC). EC is also studied 
as matrix former with lipophillic processing aids (Stearic acid, Tristearin and Trimyristin) for 
HME sustained release pellets. The purpose of this project was to study the effect various levels 
of processing aid with Ethyl cellulose matrices utilizing melt extrusion techniques. All of the 
processing aids decreased the Tg of Ethocel
TM
, which facilitated the extrusion process. With 
addition of Stearic acid (10%w/w), the Tg of the EC matrix decreased from 132.6±2.5°C to 
125.4±1.7°C. FTIR spectra of extruded pellets of EC with lipophillic processing aids indicated 
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band shift when compared to the spectra of pure EC suggesting intermolecular interaction 
between EC and lipophillic processing aids. 
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 1 
CHAPTER – 1 
INTRODUCTION 
Hot melt extrusion (HME) is an established manufacturing process that has been used in the 
plastics and food industry since 1930s (1). A number of research groups have demonstrated the 
HME process as being a viable technique for the preparation of a variety of pharmaceutical drug 
delivery systems including granules, pellets, sustained release tablets, transdermal and 
transmucosal drug delivery systems and implants. 
Table 1-1: Examples of solving pharmaceutical challenges via HME (2-3). 
S. No. Issues Solutions by HME 
1 
Poor (Unreliable/low) 
bioavailability due to poor 
API solubility 
Use of HME to prepare solid solution and solid 
dispersion (enhanced dissolution). 
2 Poor taste of API Use of HME to prepare taste masked dosage forms. 
3 
Unreliable sustained release 
action 
Uses of HME to prepare sustained release dosage 
forms (single or multiple units). 
4 Manufacturing films 
Use of HME to prepare oral strips or dermal 
patches. 
 
1.1 Extruder Assembly 
For the present studies we used a co-rotating twin screw extruder with a screw diameter of 16 
mm and a barrel length of 640 mm. The length of the screws in the extruder is given in terms of 
L/D ratio (length of the screw to the screw diameter), which in this case is 40:1 (Figure 1-1). 
This extruder can be operated at maximum screw speed of 500 rpm, operating temperature up to 
300 ºC and maximum operating pressure of 100 bars (4).The extruder consists of two screws 
 2 
which are designed to move in co-rotating manner and are driven by an AC drive. These two 
screws are assembled with the standardized screw elements, mainly involved in conveying and 
kneading or mixing (5). The conveying elements are installed at the beginning and end of the 
extruder, working jointly to transport the melted material to the die plate (Figure 1-1 and 1-3). 
The kneading elements are assembled in the middle of the extruder at various angles to generate 
shear forces through mechanical energy input, support the melting process and the 
homogenization of the melt. In general, kneading elements with a higher advance angles have 
higher mixing and shearing properties than the ones with lower angle (5). The first kneading unit 
consists of four elements with three increasing twist angles of 30°, 60°, and 90° which result in 
an optimum mixing and shearing of the powder blend (Figure 1-2). 
In the current research, powder ((carrier with active pharmaceutical ingredient (API)) was fed 
into the extruder through feeding zone 1. The material was heated with initial melting/softening 
in the initial zones. Thereafter the material was mixed and homogenized by kneading elements 
and was then transported by conveying elements to the end of the extruder through a die which 
can shape the extruded material into films or rods etc. 
 
Figure 1-1: Twin screw extruder (4) 
 3 
 
Figure 1-2: Kneading or mixing elements of advance angles (5) 
 
 
Figure 1-3: Conveying elements (5) 
Extruded films were cooled over chill rolls (Figure 1-4 and 1-5). In addition, the chill rolls 
facilitated collection of the films. Thickness of the films can be adjusted using the speed of upper 
and lower chill rolls. These films were mainly studied for trans-mucosal drug delivery systems. 
The rod shaped extrudates were cut into a specific pellet length by means of a pelletizer (Figure 
1-6). The pellets or milled extrudates were filled into the capsules or further pulverized and 
compressed into tablets. 
90º 60º 30º 
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Figure 1-4: Chill rolls for cooling extruded films (4) 
 
Figure 1-5: Schematics of extruded films utilizing chill rolls (4) 
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Figure 1-6: Pelletizer (4) 
1.2. Investigation of Cellulose ethers, Hypromellose esters and Sugar alcohols, as solid 
dispersion carrier matrix utilizing HME 
Solid dispersion is defined as the dispersion of an API in one or more inert carrier(s) or a 
hydrophilic matrix in the solid state. Solid dispersions have widely been used in clinical 
formulation development as a successful approach to deliver poorly water soluble APIs and 
improve the exposure in both experimental animals and human subjects (6). There are a variety 
of approaches to prepare solid dispersions (Figure 1-7) using the polymers as carriers, such as 
hot-melt extrusion (HME), freeze drying (FD) and solvent co-precipitation (CP) (7-8). 
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Figure 1-7: Manufacturing processes chart used to produce solid dispersions (7). 
HME is a viable method to prepare solid dispersions without using organic solvents. It represents 
an efficient and continuous manufacturing process with no further drying or discontinuous 
process steps as involved in FD and CP, respectively.  
Polymeric carriers have been the most successful excipients for solid dispersions attributed to 
their ability to form amorphous solid solutions (7). In the present study, Efavirenz (EFZ) (Figure 
1-8) was used as a model API to design formulations to enhance solubility of EFZ utilizing water 
soluble cellulose ethers-Hydroxy ethyl cellulose (HEC, M.W~90,000 g/mol), Hydroxy propyl 
cellulose (HPC, M.W~80,000 g/mol) and Hydroxy propyl methyl cellulose or Hypromellose 
(HPMC, M.W~95,000 g/mol) to form solid dispersions via hot melt extrusion (HME). 
Hypromellose ester derivatives-Hypromellose acetate succinate (HPMCAS, M.W~18,000 g/mol) 
and hypromellose phthalate (HPMCP, M.W~45,600 g/mol) were investigated as carriers for the 
ease of processability, physical stability and dissolution behavior of model API. These 
synthetically modified natural cellulose polymers are traditionally used as enteric-coating agents, 
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film-forming agents and more recently as solubility enhancing agents. The results obtained from 
our studies could provide us a wide choice of polymers in HME formulation development. EFZ 
is an approved HIV-1 reverse transcriptase inhibitor for the treatment of HIV-1 infections in 
combination with other anti-retrovirals. It is a crystalline, non-hygroscopic and lipophilic (log P 
of 5.4) material with an aqueous solubility of 9.2 µg/mL (pH 8.7) at 25 ºC (9). EFZ was extruded 
with water soluble carriers to form a number of solid dispersions. These solid dispersions were 
then characterized for release profiles and solid state characteristics using Differential scanning 
calorimetry (DSC), powder x-ray diffraction (PXRD) and Fourier Transform Infra-red 
Spectroscopy (FTIR). 
Table 1-2: Classification of Solid dispersions (10-11) 
  
Glassy 
solid 
solution 
Solid 
solution 
Glassy suspension Eutectic 
Amorphous 
Precipitation 
Phases 1 1 2 2 2 2 
Drug 
Molecularly 
dispersed 
Molecularly 
dispersed 
Amorphous Crystalline Crystalline Amorphous 
Carrier Amorphous Crystalline Amorphous Amorphous Crystalline Crystalline 
 
The molecular weights of the cellulose derivative polymers used in solid dispersions are 
literature values determined using size exclusion chromatography. In polymer industry cellulose 
derivative polymers, molecular weight is not routinely measured. This is probably because the 
direct measurement of molecular weight generally requires an expensive and complicated 
analytical system. Instead, solution viscosity, which is related to molecular weight, is usually 
employed to monitor quality because it is a simple, easy and reproducible method. 
Water-soluble carriers such as sugar alcohols (Mannitol, Sorbitol and Xylitol) have recently 
attracted a considerable interest in improving the dissolution rate, and hence possibly 
bioavailability of hydrophobic drugs. However, their utility as a primary matrix in melt extrusion 
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has not been studied. The present work also focuses on the formulation of the poorly water-
soluble drug Carbamazepine (CBZ, Figure 1-8) using sugar alcohols as carriers. CBZ is an 
imperative anti-epileptic agent that has been in use for over 30 years. It is an example of a water-
insoluble drug that requires relatively high dosing (>100 mg/day) to attain a therapeutic effect 
(12). CBZ poses multiple challenges for oral drug delivery, including a narrow therapeutic 
window, auto induction of metabolism and dissolution-limited bioavailability. CBZ crystallizes 
in at least four anhydrous polymorphic modifications and has been shown to form several 
solvates, including a stable dihydrate from aqueous solutions. A marketed formulation of CBZ 
such as Tegretol
®
 contains it’s pharmaceutically acceptable P-monoclinic or form III (12). 
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1.3 Taste masking utilizing HME 
Another drawback with EFZ pharmacotherapy is that it irritates oral mucosa. The burning mouth 
syndrome (BMS) leads to an unplanned interruption of antiretroviral pharmacotherapy (13). In 
this study, we have designed formulations using Eudragit
®
 EPO (M.W= 47000 g/mol) as carriers 
for solid dispersions. Eudragit
®
 EPO is a copolymer based on dimethylaminoethyl methacrylate 
and neutral methacrylic esters (14). It is soluble below pH 5.5. This polymer matrix can prevent 
the release of the water soluble drugs in saliva (pH 6.8–7.4) and readily dissolves in the gastric 
fluids (pH 1.0–1.5) (14). It is a very popular polymer for moisture protection and masking bitter 
or unpleasant tastes. 
 
 
 
 
Efavirenz 
 
 
 
Figure 1-8: Chemical structures of model poorly water soluble drugs 
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1.4 Development of sustained release pellets using HME 
A modified release dosage form is one for which the drug release characteristics of time course 
and/or location are chosen to accomplish therapeutic or convenience objectives not offered by 
conventional dosage forms such as solutions, ointments, or promptly dissolving dosage forms. 
Controlled or modified release systems are characterized by their ability to either control the rate 
or the area of drug release. With respect to oral drug delivery, the release can either be sustained 
during the transit of the dosage form in the gastro-intestinal tract (extended, sustained or 
prolonged drug release), or delayed to regions subsequent to the stomach including the small 
intestine or the colon (delayed release) (14). 
Sustained release (SR) delivery systems for oral dosing are effective in achieving ideal therapy 
with drugs that are eliminated rapidly or have a narrow effective range of the blood 
concentration. The drug may be embedded in a release-controlling matrix (matrix systems) or 
inside a core surrounded by release-controlling shell or a membrane (reservoir system) (15). 
Controlled delivery dosage forms can further be classified as single-unit (monolithic) or 
multiple-unit systems. Multiple-unit dosage forms with modified release properties yield 
advantages over monolithic systems in terms of beneficial pharmacokinetic properties and 
formulation flexibility. Multiparticulate oral dosage forms offer several advantages over 
monolithic systems (15). The pellets disperse rapidly and more uniformly along the gastro-
intestinal tract, reducing food effects on drug absorption and avoiding high local drug 
concentrations. The bioavailability of certain drugs can be enhanced in terms of increased 
absorption and minimized inter- and intra-subject variability. Enteric or sustained release pellets 
can either be matrix type or the reservoir type. The drug containing a core of reservoir-type 
pellets is traditionally produced by wet-mass extrusion/spheronization or by layering of the drug 
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onto nonpareils. A functional coating is then applied to the pellets in subsequent steps. Matrix 
systems may be produced by wet-mass extrusion and spheronization, melt granulation or hot-
melt extrusion using control-release carriers (15). 
During hot-melt extrusion, a blend consisting of a drug, a thermoplastic carrier and further 
optional excipients is transported through a heated barrel by one or two rotating screws. The drug 
is homogeneously dispersed in the softened carrier and then extruded under high pressure 
through a product-shaping die to yield a matrix-type dosage form. The initial porosity of melt 
extruded matrices is low due to the high degree of carrier coalescence during thermal 
compounding as compared to wet-massed or directly compressed matrices, minimizing 
percolation effects and hence drug diffusion. 
Ethyl cellulose (EC) is a hydrophobic, thermoplastic polymer used in sustained release drug 
delivery systems. EC is available in various molecular weights, and has a Tg of 129–133 °C and 
a crystalline melting point 180 °C. EC is a good candidate for extrusion because it exhibits 
thermoplastic behavior at temperatures above its glass transition temperature and below the 
temperature at which it exhibits degradation (250 °C). The use of platicizers in HME formulation 
with polymers reduces the Tg of polymers with high Tg’s and therefore permit processing at 
lower temperatures. These plasticizers may also increase the release rate by increasing flexibility 
of extruded pellets or films. In present studies, Ethylcellulose (Ethocel™ 7FP, Viscosity~7cps) 
was studied as matrix former with lipophillic processing aids (Stearic acid, Tristearin and 
Trimyristin) for HME sustained release pellets. The use of lipophillic plasticizer was found to be 
efficiently lower the required processing temperatures and maintain the sustained release. 
Chlorpheniramine Maleate (CLPM, Figure 1-9) and Diltiazem Hydrochloride (DTZ, Figure 1-9) 
were used as a model APIs. 
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Chlorpheniramine Maleate 
 
 
Diltiazem Hydrochloride 
Figure 1-9: Chemical structures of model water soluble drugs. 
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CHAPTER - 2 
OBJECTIVE 
2.1 Solid Dispersions utilizing HME 
Solid dispersions utilizing HME present the pharmaceutical industry with endless possibilities 
with regard to the formulation of poorly soluble drugs. These systems provide pharmaceutical 
scientists with several opportunities to elucidate their physicochemical characteristics. The solid 
dispersions are formulated with hydrophilic polymers as carriers, which greatly influence 
processability in HME, release characteristics and crystallization rate of APIs. Thus, the primary 
goal of this research was to investigate the viability and suitability of cellulose ethers and ester 
derivatives polymers, as well as sugar alcohols as carriers in designing solid dispersions. The 
studies were aimed to elucidate of the mechanism of drug release from extruded formulations, 
the prediction of drug carrier miscibility, and the stability of melt extruded systems. The 
behavior of the HME formulations was compared to the behavior of the respective physical 
mixtures to examine the effect of the processing on API solid state and release characteristics. 
The solid state of API in the extrudates was evaluated with differential scanning calorimetry 
(DSC), powder X-ray diffraction (PXRD) and Fourier Transform Infrared (FTIR). 
2.1.1. To investigate cellulose ethers (hydroxyl ethyl cellulose (HEC), hydroxyl propyl cellulose 
(HPC) and hydroxyl propyl methyl cellulose (HPMC)) as carriers for solid dispersions of 
Efavirenz utilizing hot melt extrusion. 
2.1.2. To evaluate Hypromellose (Hydroxypropyl methyl cellulose, HPMC), Hypromellose ester 
derivative (Hydroxypropyl methyl acetate succinate, HPMCAS and Hydroxypropyl methyl 
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phalate, HPMCP) polymers as carriers for solid dispersion of Efavirenz utilizing hot melt 
extrusion. 
2.1.3. To study the utility of sugar alcohols (Mannitol, Sorbitol and Xylitol) as solid dispersion 
carriers for a poorly water soluble drug (Carbamazepine). 
2.1.4. To develop taste masking formulations of Efavirenz with Eudragit 
®
EPO utilizing hot melt 
extrusion (HME). 
2.2. Sustained release pellets 
2.2.1. To develop ethyl cellulose based matrices with lipid based processing aids for sustained 
release with the water-soluble model drug (Chlorpheniramine Maleate and Diltiazem 
Hydrochloride). 
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CHAPTER - 3 
CELLULOSE ETHERS (HYDROXYL PROPYL CELLULOSE, HYDROXYL ETHYL 
CELLULOSE AND HYDROXYL PROPYL METHYL CELLULOSE) AS CARRIERS 
FOR SOLID DISPERSION OF EFAVIRENZ UTILIZING HOT MELT EXTRUSION 
3.1. ABSTRACT 
The objective of the present research was to utilize hot melt extrusion (HME) techniques to 
convert the crystalline form of Efavirenz (EFZ) to a more soluble amorphous form by employing 
hydrophilic matrices of cellulose ethers (HEC, HPC and HPMC). The solid state characteristics 
of EFZ in pre-extrusion physical mixtures and post-extrusion in extruded formulations in 
cellulose ether matrices were studied utilizing FTIR, DSC and PXRD. The results of this study 
indicate that formulations of EFZ in HPMC matrices exhibited the most optimal release 
characteristics followed by HEC and HPC. This may be attributed to the aqueous solubility 
and/or swelling behavior of the selected polymers. The relationship between the swelling and 
erosion process of the polymeric matrices and release pattern of EFZ from the solid dispersions 
was evaluated. The physical and chemical stability of EFZ under various storage conditions (4 
ºC, 25 ºC/60% RH and 40 ºC/75% RH) were studied. In conclusion, HPMC was found to be the 
most promising of the three polymers tested as it provided a stable solid dispersion with 
enhanced dissolution compared to HEC and HPC. However, based on the DSC studies, the re-
crystallization of the EFZ was observed in formulations with 50% w/w after 6 months in HPMC 
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formulations. Drug load exhibited a profound effect on release characteristics and stability of 
these solid dispersions. 
Keywords: Cellulose ethers; Hot melt extrusion; Swelling and Erosion process; Recrystallization. 
3.2. INTRODUCTION 
Water-soluble cellulose ether polymers are used in a broad variety of industrial applications such 
as food products, adhesives, paints, textiles and paper. In the pharmaceutical industry, cellulose 
ethers have also found a widespread use. Over 4000 pharmaceutical products listed in the 
Physician’s Desk Reference are formulated with cellulose ethers (16). In solid dosage forms, 
they are primarily used as tablet binders, film-coating agents and serve as matrix for controlled 
release formulations. Water soluble cellulose ethers, such as methylcellulose (MC), 
hypromellose or hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC) and 
hydroxyethyl cellulose (HEC) are effective in forming hydrophilic matrix in vaious dosage 
forms(16). Water insoluble ethylcellulose (EC) has been mainly used as a hydrophobic coating 
material or matrix former for modifying the release of drugs from oral dosage forms. 
For drugs with low aqueous solubility in crystalline form, formulation with respective 
amorphous forms present the possibility of improving their solubility, dissolution rate and 
bioavailability. The rationale behind this strategy is that highly disordered amorphous materials 
have a lower energy barrier to overcome in order to enter into solution than a regularly ordered 
crystalline solid. For solid dispersion applications, the aliphatic-hydroxyl groups of natural 
cellulose and synthetic 2-hydroxypropyl groups are capable of forming hydrogen bonds to APIs 
with hydrogen-bond accepting groups. The backbone of HEC, HPC, and HPMC, whose 
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molecular structures are shown in Figure. 3-1, is cellulose, which is composed of glucose 
residues joined by β-1,4 linkage. 
The carefully formulated solid dispersion of poorly soluble APIs may enhance solubility as well 
as improve the bioavailability in GIT milieu. The API is highly dispersed in the polymer matrix 
(usually at the molecular level or in microcrystalline phase); solid dispersion systems provide a 
large surface area of the compounds for dissolution process, which greatly improves the 
dissolution. Therefore, the absorption of these compounds can be improved, if intestinal 
permeability is not the limiting factor, i.e. biopharmaceutical classification system (BCS) class 2 
compounds. The model drug EFZ is classified as BCS class II compound. In the present study, 
hydrophilic matrices comprising of three different cellulose ethers HEC, HPC and HPMC were 
compared utilizing HME for solubility enhancement of EFZ via solid dispersion. The cellulose 
ethers have the potential to form hydrogen bonds with EFZ and therefore become stable within 
the amorphous form. 
 
Figure 3-1: Structures of Cellulose ethers 
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3.3. MATERIALS 
Natrosol
® 
hydroxyethylcellulose (HEC), Natrosol
® 
 250 L Pharm , Benecel
®
 hypromellose 
(HPMC), Benecel
®
 Pharm Type 2910 E 5 and Klucel
®
 hydroxypropylcellulose (HPC), Klucel
®
 
EF, were provided by Ashland Aqualon (Wilmington, DE). Efavirenz (EFZ) was purchased from 
Shreeji Pharma International, India. Silicon dioxide (Aerosil
® 
200) was provided by Degussa 
Röhm America (Piscataway, NJ). Microcrystalline cellulose (Avicel
® 
PH-112) and 
croscarmellose sodium (Ac-Di-Sol
® 
SD 117) was supplied by FMC Corporation (Newark, DE). 
3.4 METHODS 
Cellulose ethers (HEC, HPMC and HPC) were geometrically blended with EFZ at 25% w/w and 
50% w/w, respectively. The blends were manually fed through a hopper into an extruder barrel 
(16mm Prism Euro Lab, Thermo Fisher Scientific, Staffordshire UK) and processed at 
temperatures between 90 and 150 °C. The screw speed was set to a 70 rpm, while torque 
maintained below 70 N, and the pressure 60 psi. The formulation strands were manually 
collected, and stored at 4 ºC. These strands were pelletized using pelletizer in Chapter 1, Figure 
1-6. The pellets were pulverized using a sieve mesh size “22” according to US ASTM standards 
in a comminuting mill (FITZPATRICK, Model “L1A”). The milled extrudates so obtained, were 
blended with the excipients listed in Table 3-1 and filled in soft gelatin capsules (size # 2). 
Table 3-1: Capsule formulation in cellulose ether matrix used in vitro release studies. 
S. No.  Function % w/w 
1 Extruded milled powder/Physical mixtures  API carrier 83 
2 Microcrystalline Cellulose  Dispersing agent 8 
3 Silicon dioxide  Anti-adherent 2 
4 Sodium Coscarmellose  Super-disintegrant 7 
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Figure 3-2: Comparative dissolution of poorly water soluble drug from surface active carrier vs 
non surface active vehicles (6). 
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3.5. DETERMINATION OF MISCIBILITY OF EFZ IN POLYMERIC MATRICES 
When two substances completely mix with each other to form a homogeneous solution, they are 
termed miscible.(17) Miscibility is complete solubility. Solubility can be measured whereas 
miscibility is absolute. The solubility and miscibility of active pharmaceutical ingredients (APIs) 
in polymeric matrices has long been of interest in the design of pharmaceutical dosage forms 
(18). Amorphous molecular levels of dispersion of API in polymeric matrices is one of the 
examples of such dosage forms. The term miscibility is used to refer to the formation of a single 
phase amorphous system through liquid/liquid mixing, where one liquid is an amorphous 
polymer and the other liquid is an amorphous API (17, 19). Molecular level mixing can be 
achieved either by dissolving of each component in a mutual solvent followed by solvent 
removal or by directly mixing the two liquids. The latter method is normally accomplished by 
melting the crystalline API and mixing the melt with the polymer using a technique such as melt 
extrusion (20-21). In order to form a one-phase mixture during the preparation stage, the two 
liquids have to be thermodynamically miscible. The system must re-equilibrate at the post-
processing conditions and may remain a single phase or become metastable or unstable. In order 
to modify the physical stability of the API, molecular level mixing with the polymer is desirable, 
thereby altering the local environment of the API. If the two components are immiscible, the 
properties of the pure amorphous solid will largely dominate the crystallization behavior of the 
mixture and effects of the polymer on physical stability will be limited (20).  
DSC thermograms (n = 3) of physcial mixtures of EFZ and cellulose ethers with different drug 
loads (10% to 90%) were analyzed using a two step method: Initial heating step at 10 ºC/min. 
followed by cooling at 40 ºC/min. and a second heating at 10 ºC/min. after cooling the samples. 
The instrument was calibrated for temperature and heat flow using high purity standards of 
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indium and zinc, respectively. DSC can be used for the estimation of the miscibility of solid 
drugs dispersed in polymeric matrices (22). The method was based on the simple principle that 
the fraction of a drug solubilized within the matrix does not contribute to the melting endotherm 
associated with the dispersed drug fraction (23-24).  
3.6. POWDER X-RAY DIFFRACTION 
The studies were performed on a D-8 Advance X-ray Diffractometer (Bruker-Axs) equipped 
with a Sol x detector and Diffrac Plus1 software. The generator voltage and current were 40 kV 
and 40 mA respectively. The step size was 0.01º and the dwell time at each step was 1 sec. The 
crystalinity of the EFZ in the hot-melt extruded pulverized powder and their respective physical 
mixtures was analyzed using X-ray Diffractometer. The generator operating voltage and current 
were 40 kV and 40 mA, respectively. The scanning speed was 2ºper min, and the 2θ scanning 
range was from 5º to 50º. 
3.7. SOLUBILITY PARAMETERS 
The cohesive energy of a material is the energy which holds that substance together. It is the 
amount of energy required to separate the constituent atoms or molecules of the material to an 
infinite distance, and hence it is a direct measure of the attraction that its atoms or molecules 
have for one another. Cohesive energy is the net effect of all the inter atomic/molecular 
interactions including Van der Waals interactions, covalent bonds, ionic bonds, hydrogen bonds, 
electrostatic interactions, induced dipole and permanent dipole interactions (25). 
Cohesive energies are especially important to the pharmaceutical material scientists because they 
determine many of the critical physico-chemical properties (e.g. solubility, melting point) of 
drugs and excipients. The cohesive energy of a material can be quantified in a number of ways. 
The most common approach is to use the solubility parameter (δt). 
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The solubility parameter (δ) is an intrinsic physicochemical property of a substance. Various 
authors have sub-divided the total solubility parameter into components which express the 
contributions from the different types of interatomic/intermolecular forces (e.g. dispersion forces 
(δd), hydrogen bonds (δh), 'polar' interactions (δp). Solubility parameter calculations were 
performed using Molecular Modeling Pro software (Chem SW Inc., Fairfield, CA) utilizing 
group contribution approaches (Molecular Modelling Pro., 2006). For cellulose ethers, solubility 
parameters were calculated based on the single repeating monomer unit. 
The difference between the solubility parameters (∆δt) of two materials gives an estimation of 
the likelihood that they will be miscible. Compounds with similar values for δt are likely to be 
miscible because the energy of mixing from intramolecular interactions is balanced with the 
energy of mixing from intermolecular interactions. Greenhalgh et. al. demonstrated that 
compounds with ∆δt < 7 MPa1/2 were likely to be miscible and compounds with ∆δt > 10 MPa1/2 
were likely to be immiscible (26). 
3.8. FOURIER TRANSFORM INFRARED (FTIR) SPECTROSCOPIC ANALYSIS 
Fourier transform infrared (FTIR) spectra for the EFZ and cellulose ethers were obtained using a 
Perkin-Elmer spectrometer (Perkin-Elmer Life and Analytical Sciences, Shelton, CT, USA). A 
spectrum was collected for each sample within the wave number region 4,000–650 cm−1. For 
analysis the samples of EFZ in cellulose ethers, physical mixtures and pellets with various drug 
load (25 and 50% w/w) were accurately weighed containing equivalent amount of Efavirenz in 
all the samples. The spectrums were analyzed for the absence or shift in the wave numbers of the 
characteristic peaks. FTIR studies were done to detect the possible interactions between the EFZ 
and cellulose ethers in the solid dispersions (27). 
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3.9. IN VITRO RELEASE STUDIES 
In vitro release studies were performed according to USP 31 apparatus I using discriminatory 
dissolution medium comprised of 1000 ml of 0.2% SLS in distilled water. Hanson SR8-plus™ 
dissolution test station (Chatsworth, CA) was used at 37±0.5°C and paddle speed was maintained 
at 50 rpm. An amount (250 mg) equivalent to 50 mg and 100 mg of EFZ from both the physical 
mixtures and the milled extrudates with 25% and 50%w/w drug loads respectively, were blended 
with the excipients listed in Table 3-1 and filled in gelatin capsules (siz e# 2).The sinkers were 
used to immerse the capsules, avoid the floating on surface, and minimize sticking to the walls of 
the dissolution vessel. Samples were collected at predetermined time intervals, using 0.2-micron 
nylon filter tips attached to a 1 ml syringe. These samples were analyzed using HPLC/UV. All 
the results were reported as the average of 3 replicates ± SD. Dissolution profiles were compared 
using similarity factor (f2). An f2 value larger than 50 indicates that the two dissolution profiles 
are similar (29). 
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3.10. POLYMER SWELLING AND EROSION STUDIES 
In general, upon contact with dissolution medium, cellulose ethers in formulations start to swell, 
forming a gel layer around the dry core (28). The dry core of cellulose ethers polymers is glassy; 
the drug contained in them cannot diffuse unless swelling takes place. On swelling, drug 
molecules dissolve in water and are released by diffusion or erosion (Figure 3-2). Swelling and 
water sorption of polymer is a function of polymer chemical structure and polymer water 
interaction (29). Also, following HME, the extrudates have reduced porosity (30-31).  
The rate of dissolution medium uptake by the polymer were determined by equilibrium weight 
gain method (Swelling studies), and the erosion studies were performed by method similar to 
Bhisle et al (32). Both the studies were conducted using the same conditions for in vitro release 
studies. The pre-weighed milled extrudates (approx 200 mg) (W1) were filled into the gelatin 
capsules, immersed in 1000 ml of 0.2% SLS maintained at 37±0.5 
º
C in the dissolution vessel 
and paddle speed set to 50 rpm. The milled extrudates subjected to this study were removed from 
the dissolution baskets at predefined time intervals the excess water on their surfaces would be 
blotted with a tissue paper, and the swollen matrix would be reweighed (W2) (32). These 
matrices were dried to a constant weight in a hot-air oven at 60 
°
C,and the dried matrix would be 
reweighed (W3). The percentage swelling (S), and the percentage matrix erosion (E) at time, t 
were calculated using equations 3-1 and 3-2, respectively. 
S = (W2-W1) x 100    Equation 3-1 
         W2 
 E = (W3) x 100     Equation 3-2 
        W1 
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Figure 3-3: Schematic of solublization of solid dispersions with cellulose ethers as carrier 
polymers in a capsule (33). 
3.11. STABILITY STUDIES 
The sample of each of the solid dispersions were transferred to HDPE bottles and placed inside 
humidity chambers pre-equilibrated to 25 ºC/60% RH and 45 ºC/75% RH. At specific time 
interval during the course of study 6 months, the HDPE bottles assigned for each time point 
would be removed. The solid dispersions of EFZ with cellulose ether matrices were 
characterized using DSC and in vitro release studies. 
3.12. RESULTS AND DISCUSSION 
3.12.1. MISCIBILITY OF EFZ IN CELLULOSE ETHERS 
During the first heating cycle, physical mixtures containing 30% w/w EFZ in HPC matrix did not 
demonstrate a melting peak (Figure 3-6). This indicates that EFZ is completely soluble within 
the polymer matrix with drug load 30% w/w. In Figure 3-7, the thermograms indicate absence of 
the melting endotherm corresponding to EFZ in the physical mixtures containing 20% w/w EFZ 
in HPMC matrix. The thermograms of physical mixtures containing 30-50% w/w EFZ in HPMC 
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matrix exhibited diffused endotherm corresponding to EFZ indicating partial solubility. 
Therefore, this study indicated that at drug loads below 20% w/w of EFZ is completely soluble 
in the HPMC matrix and drug loads below 30% w/w of EFZ is completely soluble in the HPC 
matrix. The drug hence will form saturated solid solutions when the drug load is above 20% w/w 
in HPMC matrix and 30% w/w in HPC matrix. However, the thermograms of HEC and EFZ 
physical mixtures demonstrated endothermic peaks at 10-90% w/w in the first heating cycle in 
Figure 3-4. This data is instrumental in prediction of EFZ miscibility and solubility in cellulosic 
matrices. 
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3.11.2. SOLUBILITY PARAMETER 
The difference in the solubility parameters (∆δt) of EFZ with cellulose ethers is lower than the 
proposed value of <7 MPa
1/2 
which is required for the polymer–drug miscibility (26). HPC and 
HPMC would be expected to form stable glass solutions with EFZ (Table 3-4). HEC may be 
immiscible above certain concentration (25-26). EFZ solubility parameter was calculated as 
follows: 
δd = 22.6, δp = 5.9 and δh = 7.5 
δt = √ δd 
2
 + δp
2
  + δh 
2
   Equation 3-3 
δt = 24.5 
Table 3-2: Calculated solubility parameters for EFZ and Cellulose Ethers 
S. No.  δt ∆δt 
1 EFZ 24.5 0 
2 HEC 30.3 5.8 
3 HPC 23.1 1.4 
4 HPMC 25.6 1.1 
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3.12.3. THERMAL ANALYSIS 
The DSC thermogram of EFZ exhibited a sharp endothermic peak between at 137-139ºC 
corresponding to its melting point. DSC analysis of crystalline EFZ showed a single sharp 
endothermic peak in the temperature range of 137.54± 0.7°C and ∆Hf=51.1±2Jg
–1
 at a heating 
rate of 10°C/min
–1
. Quench-cooled EFZ exhibited a glass transition temperature of 34.45 ± 2.1°C 
(onset Tg) and no other exothermic peak of crystallization or endothermic peak of melting was 
observed. When amorphous EFZ is heated above Tg at a rate as low as 1°C /min, amorphous 
EFZ does not crystallize spontaneously. The glass-forming tendency is related to the ease with 
which the glassy state can be obtained. A measure of glass forming tendency is given by the ratio 
Tg/Tm, and for an “excellent glass former”, Tg/Tm > 0.7. Therefore, EFZ, with Tg/Tm = 0.82, is 
expected to be an excellent glass former. The following properties of amorphous EFZ are 
amenable for the preparation of solid dispersions containing amorphous EFZ: high apparent 
aqueous solubility, glass forming tendency and reasonable physical stability. 
In a solid dispersions with cellulose ethers, there are several possibilities for the distribution of 
EFZ, depending on the solid-state solubility in the polymer, a molecular glassy solid solution or 
a suspension may be formed. The thermograms of extrudates with 25% and 50%w/w EFZ in 
HEC and HPC matrix indicated absence of crystalline endothermic peak (Figure 3-7 and 3-8). 
However, the extrudates with 50% w/w in HEC and HPC exhibited the Tg at the same 
temperature as pure drug (Figure 3-4). The extrudates with 50%w/w EFZ in HPMC matrix 
demonstrated increase in Tg to 47.84±0.67°C, suggesting antiplasticizing effect of HPMC. 
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Figure 3-4: DSC profile of crystalline Efavirenz. The sample(~5 mg) was heated from -10 to 
180 °C with a heating rate of 10 °C/min, cooled at 40 °C/min to -10 °C and then heated again -10 
to 180 °C with a heating rate of 10 °C/min. 
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Figure 3-5: First Heating cycle from 30 °C to 200 °C at 10 °C/min of EFZ with different drug 
loads with HEC. 
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Figure 3-6: First heating cycle from 30 °C to 200 °C at 10 °C/min of EFZ with different drug 
loads with HPC. 
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Figure 3-7: First Heating cycle from 30 °C to 200 °C at 10 °C/minute of EFZ with different drug 
loads with HPMC. 
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Figure 3-8: DSC thermograms of extruded and physical mixtures (Phy.Mix.) of EFZ with drug 
loads, 25% and 50% w/w in HEC matrix.  
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Figure-3.9: DSC thermograms of extruded and physical mixtures (Phy.Mix.) of EFZ with drug 
loads, 25% and 50% w/w in HPC matrix. 
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Figure 3-10: DSC thermograms of extruded and physical mixtures (Phy.Mix.) of EFZ with drug 
loads, 25% and 50% w/w in HPMC matrix. 
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3.12.4. POWDER X-RAY DIFFRACTION (PXRD) 
The crystalline Efavirenz is characterized by a PXRD pattern comprising of 2 Theta values of 
6.8±0.2, 10.3±0.2, 10.8±0.2, 14.1±0.2, 16.8±0.2, 20.0±0.2, 20.5±0.2, 21.1±0.2 and 24.8±0.2 
(34). The drug was found to be in amorphous state within the extrudates. The PXRD patterns of 
the extrudates showed no crystalline peaks corresponding to EFZ compared to corresponding 
physical mixtures (Figure 3-11 to 3-13). These findings are in agreement with thermal analysis 
results. 
 
Figure 3-11: PXRD patterns of hot melt extruded pellets and physical mixtures with 25% and 
50% w/w drug load in HEC matrix. 
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Figure 3-12: PXRD patterns of hot melt extruded pellets and physical mixtures with 25% and 
50% w/w drug load in HPC matrix. 
 
Figure 3-13: PXRD patterns of hot melt extruded pellets and physical mixtures with 25% and 
50% w/w drug load in HPMC matrix. 
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3.12.5. FOURIER TRANSFORM INFRARED SPECTROSCOPY 
FTIR spectroscopy has been successfully used for exploring the differences in molecular 
conformations, crystal packing and hydrogen bonding arrangements for different solid-state 
forms of an organic compound. Spectral variations originate due to alteration in bonds that 
exhibit characteristic vibrational frequencies, leading to frequency shifts and splitting in 
absorption or transmittance of peaks.  
The chemical interactions between EFZ and cellulose ethers in the solid dispersions may 
stabilize amorphous state of EFZ. There are several reports in literature of cellulose ethers 
interaction potential with drugs [35]. The crystalline EFZ shows characteristic bands at 3311.33 
cm
-1
, 2249.86 cm
-1
, 1602.29 cm
-1
, 1745.42 cm
-1
, 1241.11 cm
-1
 and 1316.13 cm
-1
 attributed to N-
H stretching vibrations, aromatic C-H stretching vibration, C≡C stretching vibration, C=O 
stretching vibration, C-F stretching vibration, C-O-C stretching vibration, respectively. The 
bands corresponding to C=O vibrations and N–H stretching became broadened and diffused in 
case of amorphous form as shown in Figure 3-15 (1728.69 cm
-1
 and 3260.09 cm
-1
, respectively). 
This may indicate the participation of –NH and C=O groups in intermolecular hydrogen bonding 
between EFZ molecules. The spatial arrangement of EFZ molecules in the crystal lattice does not 
allow intermolecular hydrogen bonding which starts to occur once the orderliness of crystalline 
lattice is disturbed by formation of amorphous form. These intermolecular hydrogen bonds are 
relatively weak and amorphous form tends to revert back to the crystalline form. 
Cellulose ethers shows the characteristic strong bands due to ether C-O-C stretch at 1150-1060 
cm
-1
 in all three spectras in Figure 3-14. Also, HPC and HPMC contain secondary alcohol 
group’s absorption at 1150-1075 cm-1. This band is also found for the secondary alcohol groups 
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of HEC, but HEC has an additional shoulder due to their primary alcohol groups. Only, HPMC 
exhibits absorption due to methoxy groups at 1200-1185 cm
-1
 (Figure 3-14). 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
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Figure 3-14: An overlay of FTIR spectra of cellulose ethers (HEC, HPC and HPMC). 
In Figure 3-15, extruded formulation with 25 and 50%w/w EFZ in HEC matrix showed 
summation of individual components of IR spectra similar to the physical mixture. The 
characteristic peaks at 3311.83 cm
-1
 corresponding to N-H stretching and 1744.61 cm
-1
 
corresponding C=O stretching vibration indicating the absence of specific interaction with HEC. 
However, the band at 3311.33 cm
−1
 corresponding to the symmetrical N–H stretching vibrations 
of the EFZ seen in the pure drug was replaced by a broader band at the 3400 cm
−1 
in the 
extrudates with HPC and HPMC. This indicates the possible involvement of −NH2 groups in 
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hydrogen bonding with the −OH groups of HPC and HPMC. In addition, the carbonyl group 
band showed shift to higher wave numbers from 1745.42 cm
-1
 to 1755 cm
-1
 or higher in extruded 
pellets spectrum (Figure 3-16 and 3-17). These results suggest that the N–H and C=O functional 
groups of EFZ interact with the −OH groups of HPC and HPMC at 25% and 50% w/w drug load 
at the molecular level in solid dispersions, resulting in extended intermolecular interactions in the 
extruded pellets of EFZ. These results are in agreement with our DSC miscibility studies. 
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Figure 3-15: An overlay of FTIR spectra of Crystalline Efavirenz, amorphous Efavirenz and 
HEC at drug loads 25 and 50% w/w. 
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Figure 3-16: An overlay of FTIR spectra of Crystalline Efavirenz, amorphous Efavirenz and 
HPC at drug loads 25 and 50% w/w. 
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Figure 3-17: An overlay of FTIR spectra of Crystalline Efavirenz, amorphous Efavirenz and 
HPMC at drug loads 25 and 50% w/w. 
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3.12.6. RELEASE STUDIES 
The extrudates were milled and blended with excipients in order to minimize the delay in drug 
diffusion due to swelling of the cellulose ether matrix in Table 3-1. In vitro release studies 
(Figure 3-14 to 3-16) of the extrudates were found to be superior in comparison to their 
corresponding physical mixtures and pure drug (EFZ, Crystalline Efavirenz). HEC and HPMC 
melt extruded formulations demonstrated faster drug release profiles when compared to those 
containing HPC (p<0.05), which might be attributed to the aqueous solubility or hydrophilicity 
and swelling behavior of the HPC (Table 3-5). The Figure 3-2 shows the possible retarding effect 
Table 3-3: Literature values of measurement of Cellulose Ethers Hydrophilicity 
S. No.  
% water content at 
70% RH 
Surface Tension 
(mN/m) 
Hydrophilicity 
1 HEC 21.7 61 High 
2 HPMC 14.0 50 Medium 
3 HPC 10.9 45 Low 
of HPC matrix on the drug release. The formation of solid plug was observed with HPC solid 
dispersions. The delay in penetration of dissolution medium (Figure 3-15) may provide 
conditions for conversion of amorphous to crystalline form. HPMC is reported to increase the 
micro-environment viscosity and prevent re-crystallization of amorphous API. 
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Figure 3-18: Comparison of the in vitro release profiles of the 25% and 50%w/w melt extruded 
and physical mixture capsule formulations in HEC matrix. 
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Figure 3-19: Comparison of the in vitro release profiles of the 25% and 50%w/w melt extruded 
and physical mixture capsule formulations in HPC matrix. 
 
Figure 3-20: Comparison of the in vitro release profiles of the 25% and 50%w/w melt extruded 
and physical mixture capsule formulations in HPMC matrix. 
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3.12.7. SWELLING AND EROSION STUDIES 
In aqueous medium, cellulose ethers tend to form hydrogels. Individual particles swell and their 
macromolecular chains start entangling, thus creating diffusional spaces that are controlled by 
the molecular weight and hydrophilic characteristics of the carrier polymers. Evidently, the 
average distance between consecutive physical entanglements, tight junctions, or tie points in 
these physical networks is a most important molecular parameter that will control not only the 
integrity of the formed swollen network (hydrogel) but also the diffusion characteristics of the 
drug diffusing through it and being released (35). According to literature, the number of 
entanglements per chain, are lowest for HPMC, followed by, HEC and HPC. Moreover, the 
molar substitution of HPC polymer was 3.7, indicating that most hydroxyl groups are substituted 
with hydrophilic hydroxypropyl groups, providing many possibilities for interactions. 
The results of swelling and erosion studies presented in Figure 3-21 demonstrated that extrudates 
of HEC and HPMC matrices rapidly absorb dissolution medium and increase in weight over time 
until its complete disintegration around 4 hours. However, the extrudates with HPC matrices 
showed minimum swelling or erosion and their weight remained constant after 4 hours. These 
results can be correlated to our drug release data. 
 47 
 
Figure 3-21: Swelling profiles of the 25% and 50% w/w EFZ in melt extruded formulations in 
cellulose ethers (HEC, HPC and HPMC) matrix. 
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Figure 3-22: Erosion profiles of the 25% and 50% w/w EFZ in melt extruded formulations in 
cellulose ethers (HEC, HPC and HPMC) matrix. 
3. 12.8 STABILITY 
Many factors such as glass transition temperature of API, viscosity, plasticization/anti-
plasticization, storage temperature, and humidity play an important role in determining the 
stability of high-energy amorphous solid dosage forms. Cellulose ethers tend to absorb moisture 
under high humidity conditions. The formulations of EFZ in HEC and HPC demonstrated 
significant decrease in release over period of time (f2<50, Figure 3-21and 3-22). The solid 
dispersions of EFZ with HPMC exhibited significant delay in release after 3 months with 50% 
w/w drug load (f2<50, Figure 3-23). These studies would indicate that higher drug load (50% 
w/w) is prone to re-crystallization at 40 °C/75% RH (Figure 3-24 to 3-26). The moisture may 
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cause supersaturated regions led by dissolution of the drug at a micro-environmental level in the 
polymeric matrix, which eventually leads to nucleation and re-crystallization. At lower drug load 
(25% w/w), drug molecules are surrounded by higher number of polymer molecules which 
prevent the mobility of drug molecules. The chemical interactions can further impede the motion 
of drug molecules in polymer matrix and inhibit re-crystallization of EFZ. 
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Figure 3-23: Release profiles of the 25% and 50% w/w melt extruded formulations in HEC 
matrix at the initial, 1, 3 and 6 month time points following storage at 40 °C/75% RH. 
 
Figure 3-24: Release profiles of the 25% and 50% w/w melt extruded formulations in HPC 
matrix at the initial, 1, 3 and 6 month time points following storage at 40°C/75% RH. 
 51 
 
Figure 3-25: Release profiles of the 25% and 50%w/w melt extruded formulations in HPMC 
matrix at the initial, 1, 3 and 6 month time points following storage at 40°C/75% RH. 
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Figure 3-26: DSC thermogram illustrating stability Efavirenz in HEC matrix hot melt extruded 
pellets at the initial, 1, 3 and 6 month time points following storage at 40 °C/75% RH. 
 53 
 
Figure 3-27: DSC thermogram illustrating stability Efavirenz in HPC matrix hot melt extruded 
pellets at the initial, 1, 3 and 6 month time points following storage at 40 °C/75% RH. 
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Figure 3-28: DSC thermogram illustrating stability Efavirenz in HPMC matrix hot melt 
extruded pellets at the initial, 1, 3 and 6 month time points following storage at 40 °C/75% RH. 
3.13. CONCLUSIONS 
The present study demonstrated that cellulose ethers can be successfully extruded with EFZ. 
HPC and HPMC demonstrated promising EFZ solubility in polymer matrix. The data obtained 
from DSC, PXRD and FTIR studies showed that EFZ is molecularly dispersed in the HPMC and 
HPC matrices, while EFZ did not exhibit any specific interactions with HEC matrix. HEC based 
solid dispersions are susceptible to instability due to absence of interactions between EFZ and 
HEC. However, solid dispersions of EFZ in HPMC matrices exhibited enhanced dissolution 
rates, attributed to the intermolecular interactions resulting in inhibition of crystallization in 
dissolution medium and increased wettability. The combination of melt extrusion and 
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hydrophilic polymers successfully resulted in amorphous solid dispersion systems with enhanced 
solubility of EFZ although cellulose ethers are susceptible to moisture absorption. This study 
demonstrates that HME could be considered as an alternative technology to improve the 
dissolution characteristics of EFZ. Additionally, this research demonstrated that formulation 
using HPMC via HME may be effective for other poorly soluble drugs. 
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CHAPTER - 4 
HYPROMELLOSE DERIVATIVE ESTER POLYMERS AS CARRIERS FOR SOLID 
DISPERSION OF EFAVIRENZ (EFZ) UTILIZING HOT MELT EXTRUSION 
4.1. ABSTRACT 
The current research investigates process-ability; physical stability and dissolution behavior of 
EFZ solid dispersions prepared using Hypromellose ester derivative polymers (HPMCAS and 
HPMCP) as carrier matrices in combination with Sodium Lauryl Sulphate (SLS, 2 and 5%w/w). 
Two different drug loads of 25 and 50%w/w were studied in each polymer system. The chemical 
interaction between EFZ and Hypromellose ester derivatives was determined using Fourier 
transform infrared (FTIR). The solid-state characterization of EFZ in the Hypromellose ester 
derivative matrix was performed using differential scanning calorimetry (DSC), Powder X-ray 
Diffraction (PXRD). The in vitro release of these solid dispersions was evaluated in pH 6.8 
phosphate buffer. Although, the drug release from solid dispersions prepared from polymers used 
for enteric coating (i.e. HPMCP) was higher compared with that of HPMCAS (p<0.05), 
HPMCAS was found to be easily process-able compared to HPMCP. The interaction between 
the HPMCAS and EFZ in polymer matrices provided stability to the amorphous EFZ in solid 
dispersions than its pure form in the amorphous phase. Upon storage at accelerated stability 
conditions, no phase separation was observed in HPMCAS solid dispersions at the 25 and 50% 
w/w levels.  
Keywords: Processability; Hypromellose ester derivatives; Phase separation Fourier transform 
infrared (FTIR), differential scanning calorimetry (DSC), Powder X-ray Diffraction (PXRD). 
 57 
4.2. INTRODUCTION 
Hypromellose (HPMC) is a natural cellulose that is chemically O-methylated and O-(2-
hydroypropylated) cellulose (36). It is available in several grades that vary in viscosity and 
extent of substitution. Hypromellose has been used as coating agent, dispersing agent, 
dissolution enhancer, emulsifying agent, tablet binder and thickening agent. Hypromellose 
acetate succinate (HPMCAS) and hypromellose phthalate (HPMCP) are synthetically modified 
mixtures of acetic acid, monosuccinic acid esters of hypromellose and 2-hydroxypropyl methyl 
ether, phthalic acid ester of hypromellose, respectively. These synthetically modified natural 
cellulose polymers are traditionally used as enteric-coating agents, film forming agents and more 
recently as solubility enhancing agents in solid dispersions. For solid dispersion applications, the 
aliphatic-hydroxyl groups of HPMC and synthetic 2-hydroxypropyl groups are capable of 
donating hydrogen bond to APIs with hydrogen bond accepting groups. In HPMCAS matrix, the 
acetyl and succinyl groups can accept hydrogen bonds from APIs to stabilize the solid dispersion 
and in HPMCP matrix pthalyl ester substituent groups are capable of donating strong bonds to 
APIs with hydrogen-bonds accepting groups. The hydrogen bond accepting carbonyl group ester 
can resonance to stabilize the carboxylic acid hydrogen bond donating group through the 
aromatic phthalate. In addition, Hypromellose based solid dispersions are reported to reduce the 
overall molecular mobility in the system, indicated by an increase in the Tg of the mixed system. 
A higher Tg value compared to the pure drug will result, or indicate that strong specific 
interactions between the drug and polymer which may stabilize the solid dispersion. 
The objective of this study was to develop a suitable amorphous solid dispersion formulation for 
a poorly water soluble compound, EFZ with Hypromellose ester derivative as carrier polymers 
using melt extrusion technique. Hypromellose and Hypromellose ester derivative polymers are 
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challenging to extrude because of their high glass transition temperature and highly viscous melt 
generated in the extruder. HPMCAS and HPMCP polymers have glass transition temperatures 
between 120-135°C and 145-150°C, respectively. However, plasticizers or plasticization by APIs 
may be necessary to effectively melt extrude HPMC and HPMC ester derivatives. In Chapter-3, 
HPMC was extruded with EFZ without addition of plasticizers. In the present study, SLS was 
used as plasticizing agent for HPMCP and HPMCAS matrices. SLS has been reported to exhibit 
its plasticizing effect by decreasing the melt viscosity and Tg of of the carrier polymers 
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Figure 4-1: Structures of Hypromellose and Hypromellose ester derivatives(36) 
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4.3. MATERIALS 
Hydroxypropyl methylcellulose (Benecel
®
, HPMC-E5 PH) was obtained from Ashland Aqualon 
Ingredients USA, Hydroxypropyl methylcellulose acetyl succinate (AQOAT, HPMCAS-LF) and 
Hydroxypropyl methylcellulose phthalate (HPMCP, HP55) were obtained from Shin Etsu, USA. 
EFZ was supplied by Ria International, East Hanover, NJ. All other materials used were of 
reagent grade. 
4.4. METHODS 
4.4.1. HOT-MELT EXTRUSION 
The polymer with various drug load (25 and 50% w/w) were mixed in a V-cone blender 
(MaxiBlendTM, GlobePharma) at 25 rpm for 15 minutes and then extruded with a co-rotating 
twin screw extruder (16 mm Prism EuroLab, ThermoFisher Scientific) into uniform rod 
extrudates at an extrusion temperature range of 100-150 °C and a screw speed of 70 rpm. The 
feed rate was adjusted so that the extruder % Torque Indicator was at approximately 60% for 
optimum extruder performance. The diameter of the extruded rods was approximately 2mm. 
These extrudates were subsequently processed into pellets of 1mm thickness using a pelletizer 
(Type L-001-9482, Thermoscientific, Stone, UK).  
4.4.2. Thermogravimetric analysis (TGA) 
Studies were performed on a Perkin Elmer Pyris 1 TGA equipped with Pyris software. TGA 
analysis was performed on HPMC, HPMCAS, HPMCP, EFZ and physical mixtures (Phy.Mix) 
with various drug loads by heating from 30-200 °C at 20° C/min. 
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4.4.3. DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
The thermograms were recorded using Perkin-Elmer Pyris 1 DSC equipped with Pyris Manager 
Software. DSC was used to study solid-state characteristics of EFZ in HPMC, HPMCAS and 
HPMCP matrix, pre-extrusion in physical mixtures and post-extrusion in extruded pellets. All the 
samples were heated from -10 °C to 180 °C at 10°C/min, cooled to -10°C (10 °C/min), and then 
reheated to 180 °C at 10 °C/min. For physical stability studies, samples of extruded pellets, 
approximately 8–10 mg, were hermetically sealed in an aluminum pan and heated from -10 °C to 
180 °C at a linear heating rate of 10 °C/min. 
4.4.4. SOLUBILITY PARAMETER 
Solubility parameter calculations were performed using Molecular Modeling Pro software 
(Chem SW Inc., Fairfield, CA) utilizing group contribution approaches (Molecular Modelling 
Pro., 2006). 
4.4.5. CHROMATOGRAPHIC CONDITIONS 
A Waters HPLC-UV system (Waters Corp, Milford, MA) and a Symmetry Shield RP C-18 
(250×4.6 mm, 5 μm) column was used at a detection wavelength of 245 nm. The mobile phase 
consisted of acetonitrile and Formic acid in water (pH =4.0) at a ratio of 60:40 (v/v). The mobile 
phase flow rate was maintained at 1.5 ml/min. EFZ retention time was 7.2±0.43 min under these 
conditions. Injection volume was 20 μl. All of the HPLC data was analyzed using Empower V. 
software. 
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4.4.6. FOURIER TRANSFORM INFRARED (FTIR) SPECTROSCOPIC ANALYSIS 
FTIR spectra for EFZ, HPMCP and HPMCAS were obtained using a Perkin-Elmer spectrometer 
(Perkin-Elmer Life and Analytical Sciences, Shelton, CT, USA). A spectrum was collected for 
each sample within the wave number region 4,000–650 cm−1. The spectrums were analyzed for 
the absence or shift in the wave numbers of the characteristic peaks. FTIR studies were done to 
detect the possible interactions between EFZ and Hypromellose ester derivatives in the solid 
dispersions. 
4.4.7. POWDER X-RAY DIFFRACTION (PXRD) 
The crystallinity of EFZ in the hot-melt extruded pellets and their respective physical mixtures 
were analyzed using X-ray diffractometry. The studies were performed on a D-8 Advance X-ray 
diffractometer (Bruker-Axs) equipped with Diffrac Plus1 software. The generator operating 
voltage and current were 40 kV and 40 mA, respectively. The step size was maintained at 0.01º 
and the dwell time at each step was 1 sec. The scanning speed was 2ºper min, and the 2 Theta 
scanning range was from 5º to 40º. 
4.4.8. IN VITRO RELEASE STUDIES  
In vitro release studies were performed according to USP 31 apparatus I using discriminatory 
dissolution medium comprised of 1000 ml of 0.2% SLS in 0.1M HCL (pH 1.2) and 0.2M sodium 
phosphate buffer (pH 6.8). Hanson SR8-plus™ dissolution test station (Chatsworth, CA) was 
used at 37±0.5 °C and paddle speed was maintained at 50 rpm. Samples were collected at 
predetermined time intervals, through a stain-less steel cannula with a 0.2 µm nylon filter tips 
attached to a 1 ml syringe. These samples were analyzed using HPLC/UV. All the results were 
reported as the average of 3 replicates ± SD. Dissolution profiles were compared using similarity 
factor (f2). An f2 value larger than 50 indicates that the two dissolution profiles are similar. 
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4.4.9. STABILITY STUDIES 
The impact of temperature and humidity conditions on the physical and chemical stability of 
EFZ in pellet formulations was determined by storing in closed HDPE bottles at 4 °C, 25°C/60% 
RH, 40 °C/75% RH and 60 °C. The dissolution profiles, chemical and physical stability of the 
pellets were examined at initial, 1, 3 and 6 month time points. The dissolution profiles of capsule 
formulations at different time points were compared using the f2 similarity factor. 
4.4.10. DATA ANALYSIS 
In all the cases, statistical analysis was performed utilizing one-way analysis of variance. A 
statistically significant difference was considered when p<0.05. 
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4.5. RESULTS AND DISCUSSION 
4.5.1. HOT MELT EXTRUSION 
The solubility parameters of EFZ, hypromellose phthalate (HPMCP) and hypromellose (HPMC), 
hypromellose acetate succinate (HPMCAS) are calculated in Table.1. The difference in the 
solubility parameters (∆δt) are lower than the proposed value of 7 MPa1/2 required for the 
polymer–drug miscibility indicating that EFZ would likely to be miscible with hypromellose 
acetate succinate (HPMCAS) and hypromellose phthalate (HPMCP). As discussed earlier 
plasticizers or plasticization by APIs may be necessary to effectively melt extrude Hypromellose 
ester derivatives. SLS has been reported to be an instrumental plasticizer, lowering the melt 
viscosity during extrusion and thereby increasing the drug solubility and homogeneity in the 
carrier polymer. In this study, two levels (2 and 5% w/w) of SLS were used. HPMCAS and 
HPMCP could not be extruded without SLS. The extruded pellets were transparent for HPMC 
and HPMCAS with drug loads of 25 and 50% w/w. The extruded pellets for HPMCP with drug 
loads of 25 and 50% w/w were turbid or white in color. As discussed in Chapter 3, the clear 
appearance signify that a solid dispersion was obtained and turbid extrudates may indicate such 
dispersions are not chemically and physically uniform throughout or comprise more than one 
phase. HPMCP is reported to form the solid dispersions with super saturated polymer matrix 
with amorphous API and heterogeneous distribution of API. When all of the EFZ has dissolved 
in the HPMCAS matrix upon melting during extrusion, a homogenous solution was formed. This 
solution upon cooling formed a solid solution and exhibited a clear appearance. The clear 
extrudates indicated a homogenous miscible system upon cooling like the ones obtained with 
HPMCAS with drug loads of 25 and 50% w/w.  
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4.5.2. THERMAL ANALYSIS 
The thermal stability of physical mixtures of EFZ, HPMC, HPMCAS and HPMCP was 
determined using (TGA). As shown in Figure 4-2, the results from the TGA study, physical 
mixtures of EFZ, HPMC, HPMCAS and HPMCP did not begin to show signs of thermal 
decomposition until reaching approximately 200 
°
C. TGA thermogram confirmed the thermal 
stability of physical mixtures of EFZ, HPMC, HPMCAS and HPMCP at the extrusion 
temperatures at drug loads 25 and 50% w/w.  
In Figure 3-4, EFZ exhibited a glass transition temperature of 34.45±2.1 °C. The Tg can be 
reported as the onset, midpoint (1/2 × change in heat capacity at the Tg), or the endset (offset) of 
the glass transition. We used midpoint by placing tangent lines of the step event seen as slight 
endothermic shifts in the baseline (Figure 4-5). It is often recommended when taking Tg 
measurements to first heat the sample above its Tg, so as to erase the effects of the sample’s 
thermal history, and cool it down to a temperature well below the Tg and then determine the Tg 
on the second heating. In the Figure 4-5 to Figure 4-9, Tg of the EFZ significantly increased in 
extruded formulations with Hypromellose ester derivative polymers compared to EFZ alone. 
Table 4-1: Calculated solubility parameters for EFZ and Hypromellose ester derivatives. 
S. No.  δt ∆δt 
1 EFZ 24.5 0 
2 HPMC 25.6 1.1 
3 HPMCAS 29.6 5.1 
4 HPMCP 30.35 5.85 
 
The anti-plasticization (increase in Tg) effect of polymeric carriers on drugs is considered 
important for stability. The increase in Tg means molecular mobility of the drug has been 
reduced which leads to a decrease in nucleation or re-crystallization of drug molecules. A single 
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Tg (indicating molecular miscibility) was observed for all of the three polymers with Tg ranging 
from 75 to 82 
°
C, as measured by DSC, immediately after the manufacture at the two drug loads 
of 25 and 50%w/w. 
 
Figure 4-2: TGA of Hypromellose (HPMC) and Hypromellose ester derivatives (HPMCAS and 
HPMCP) and EFZ at drug loads 25 and 50% w/w. 
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Figure 4-3: First heating cycle of the same sample after cooling from 30 °C to 200 °C at 10 
°C/min of EFZ with different drug loads with HPMCAS. 
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Figure 4-4: First heating cycle of the same sample after cooling from 30 °C to 200 °C at 10 
°C/min of EFZ with different drug loads with HPMCP. 
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Figure 4-5: DSC thermograms of extruded of EFZ with drug loads 25 and 50% w/w in 
HPMCAS matrix with 5% SLS; heating step (10 °C/min), followed by cooling step (40 °C/min) 
and heating step (10 °C/min). 
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Figure 4-6: DSC thermograms of extruded and physical mixtures (Phy.Mix.) of EFZ with drug 
loads 25 and 50% w/w in HPMCAS matrix with 2% SLS. 
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Figure 4-7: DSC thermograms of extruded and physical mixtures (Phy.Mix.) of EFZ with drug 
loads 25 and 50% w/w in HPMCAS matrix with 5% SLS. 
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Figure 4-8: DSC thermograms of extruded and physical mixtures (Phy.Mix.) of EFZ with drug 
loads 25 and 50% w/w in HPMCP matrix with 2% SLS. 
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Figure 4-9: DSC thermograms of extruded and physical mixtures (Phy.Mix.) of EFZ with drug 
loads 25 and 50% w/w in HPMCP matrix with 5% SLS. 
 74 
4.5.3. POWDER X-RAY DIFFRACTION (PXRD) 
The crystalline EFZ is characterized by a PXRD pattern comprising of 2 Theta values of 6.8±0.2, 
10.3±0.2, 10.8±0.2, 14.1±0.2, 16.8±0.2, 20.0±0.2, 20.5±0.2, 21.1±0.2 and 24.8±0.2. The drug 
was found to be in amorphous state within the extrudates. The PXRD patterns of the extrudates 
with Hypromellose ester derivatives matrices showed no crystalline peaks corresponding to EFZ 
compared to corresponding physical mixtures (Figure 4-10 and 4-11). These findings are in 
agreement with thermal analysis results. 
  
Figure 4-10: PXRD patterns of hot melt extruded pellets and physical mixtures with 25 and 50% 
w/w drug load in HPMCAS matrix with 2 and 5% SLS. 
 75 
 
Figure 4-11: PXRD patterns of hot melt extruded pellets and physical mixtures with 25 and 50% 
w/w drug load in HPMCP matrix with 2 and 5%SLS. 
4.5.4. FOURIER TRANSFORM INFRARED SPECTROSCOPY 
The chemical interactions between EFZ and Hypromellose ester derivative polymers in the solid 
dispersions may stabilize amorphous state of EFZ. There are several reports in the literature of 
Hypromellose ester derivative interaction potential with drugs. As mentioned earlier, the 
crystalline EFZ shows characteristic bands at 3311.33 cm
-1
, 2249.86 cm
-1
, 1602.29 cm
-1
, 1745.42 
cm
-1
, 1241.11 cm
-1
 and 1316.13 cm
-1
 attributed to N−H stretching vibrations, aromatic C−H 
stretching vibration, C≡C stretching vibration, C=O stretching vibration, C−F stretching 
vibration, C−O−C stretching vibration, respectively. The bands corresponding to C=O vibrations 
and N−H stretching diffused in case of amorphous form as shown in Figure-4a (1728.69 cm-1 
and 3260.09 cm
-1
, respectively). This may indicate the participation of −NH and C=O groups in 
intermolecular hydrogen bonding between EFZ molecules. The spatial arrangement of EFZ 
molecules in the crystal lattice does not allow intermolecular hydrogen bonding which starts to 
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occur once the orderliness of crystalline lattice is disturbed by formation of amorphous form. 
These intermolecular hydrogen bonds are relatively weak and amorphous form tends to revert 
back to the crystalline form. For pure HPMC, the absorption band of hydroxyl group at 
3449 cm−1, Hypromellose ester derivative polymers (HPMCP and HPMCAS) shows the 
characteristic bands of the ester groups at 1150-1190 cm
-1
, 1239.23 cm
-1
 and 1268.22 cm
-1
, as 
well as the C=O ester vibration at 1720-1740 cm
-1
. The physical mixtures of EFZ in 
Hypromellose ester derivatives showed summation of EFZ and polymers IR spectra. In extruded 
pellet formulations with EFZ in HPMCAS (Figure 4-10 and 4-11), the band at 3311.33 cm
-1
 
corresponding to N−H stretching in crystalline EFZ spectra disappeared. In the spectra of 
extruded pellets, the bands corresponding to C=O ester vibrations in HPMCAS exhibited shift in 
the intensity of bands at 1736-1739 cm
-1
. This may indicate presence of intermolecular 
interaction between C=O group of HPMCAS and −NH group of EFZ. The increase in 
concentration of SLS did not affect the interaction. 
In the Figure 4-12 and 4-13, with EFZ in HPMCP matrices, the band at 3311.33 cm
-1
 
corresponding to N−H stretching in crystalline EFZ spectra disappeared. In the spectra of 
extruded pellets, the bands corresponding to C=O ester vibrations in HPMCP exhibited a shift in 
intensity of the bands at 1755-1757 cm
-1 
and split in the band at 1721 cm
-1
. This may indicate the 
presence of intermolecular interaction between the C=O group of HPMCP and −NH group of 
EFZ.  The increase in concentration of SLS did not affect these interactions. 
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Figure 4-12: An overlay of FTIR spectra of cellulose ethers (HPMC, HPMCAS and HPMCP). 
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Figure 4-13: An overlay of FTIR spectra of Crystalline Efavirenz, amorphous Efavirenz and 
HPMCAS at drug loads 25 % w/w with SLS (2 and 5% w/w). 
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Figure 4-14: An overlay of FTIR spectra of Crystalline Efavirenz, amorphous Efavirenz and 
HPMCAS at drug loads 50 % w/w with SLS (2 and 5% w/w). 
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Figure 4-15: An overlay of FTIR spectra of Crystalline Efavirenz, amorphous Efavirenz and 
HPMCP at drug load 25% w/w with SLS (2 and 5% w/w). 
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Figure 4-16: An overlay of FTIR spectra of Crystalline Efavirenz, amorphous Efavirenz and 
HPMCP at drug load 50 % w/w with SLS (2 and 5% w/w). 
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4.5.6. RELEASE STUDIES 
Enteric polymers can be used for a pH-dependent controlled release dosage forms and provide 
better bioavailability because they prevent re-crystallization of the drug in the gastric juice as 
well as acid decomposition of drugs (37). Since HPMCAS and HPMCP are enteric polymers and 
dissolve in basic buffers, they are insoluble in the acidic fluid and in purified water. The extruded 
pellets were milled and blended with the excipients in Table 4-2. In vitro release studies (Figure 
4-16 and 4-17) of the extrudates were found to be superior in comparison to their corresponding 
physical mixtures and pure drug (EFZ, Crystalline Efavirenz). HPMCP and HPMCAS melt 
extruded formulations significantly improved drug release when compared to those containing 
HPMC (p<0.05), which might be attributed to the aqueous solubility or hydrophilicity and 
swelling behavior of the polymers in pH 6.8 dissolution medium. The concentration of SLS (2 
and 5%w/w) in HPMCP and HPMCAS matrices had an insignificant effect on release profiles. 
Table 4-2: Capsule with Hypromellose ester derivatives formulation used in vitro release studies. 
S. No.  Function % w/w 
1 
Extruded milled powder/Physical 
mixtures  
API carrier and solublizing 
matrix polymer 
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2 Microcrystalline Cellulose  Dispersing agent 8 
3 Silicon dioxide  Anti-adherent 2 
4 Sodium Croscarmellose  Super-disintegrant 7 
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Figure 4-17: Comparison of the in vitro release profiles of the 25 and 50% w/w melt extruded 
and physical mixture capsule formulations with 2 and 5% SLS in HPMCAS matrix in 6.8 pH 
buffer. 
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Figure 4-18: Comparison of the in vitro release profiles of the 25 and 50% w/w melt extruded 
and physical mixture capsule formulations with 2 and 5% SLS in HPMCP matrix in 6.8 pH 
buffer. 
4.5.8. STABILITY 
Upon moisture exposure in the accelerated condition (40 °C/75% RH), the plasticizing effect of 
water leads to a reduction in Tg and increase in molecular mobility of the amorphous drug. This 
may trigger the onset of phase separation and re-crystallization of EFZ as discussed in Chapter 3. 
HPMCP formulations were discontinued due to their poor process-ability. HPMCAS based solid 
dispersions were stable over the period of 6 months (Figure 4-18 to 4-21). 
The % EFZ content remaining in the formulations was greater than 98.7±0.6%; and the drug 
release profile (f2>50) remained unchanged after 6 month storage at 40 °C/75% RH (Figure 4-20 
and 4-21). EFZ melting peak was not detected by DSC even after 6 month storage at 40 °C/75% 
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RH (Figure 4-19 and 4-20). The stability of the amorphous form of EFZ could be due to 
interaction with HPMCAS (38). 
 
Figure 4-19: DSC thermogram illustrating stability Efavirenz in HPMCAS matrix with 2% w/w 
SLS hot melt extruded pellets at the initial, 1, 3 and 6 month time points following storage at 
40°C/75% RH. 
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Figure 4-20: DSC thermogram illustrating stability Efavirenz in HPMCAS matrix with 5% w/w 
SLS hot melt extruded pellets at the initial, 1, 3 and 6 month time points following storage at 40 
°C/75% RH. 
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Figure 4-21: DSC thermogram illustrating stability Efavirenz in HPMCAS matrix hot melt 
extruded pellets at the initial, 1, 3 and 6 month time points following storage at 40 °C/75% RH. 
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Figure 4-22: DSC thermogram illustrating stability Efavirenz in HPMCAS matrix hot melt 
extruded pellets at the initial, 1, 3 and 6 month time points following storage at 40 °C/75% RH. 
4.6. CONCLUSIONS 
In Chapter 3, the factors affecting the release profiles and stability of high-energy amorphous 
forms of API such as the aqueous solubility or hygroscopicity and intermolecular interaction of 
API with polymeric carriers were discussed. In the present study, relatively low hygroscopicity 
of Hypromellose ester derivatives and ability to form intermolecular interactions with APIs 
demonstrated stabilizing effect on the amorphous systems (38). The present study showed that 
Hypromellose ester derivatives can be successfully extruded with EFZ in combination with SLS. 
HPMCAS and HPMCP matrices demonstrated promising EFZ miscibility. The data obtained 
from DSC, PXRD and FTIR studies demonstrated that EFZ is molecularly dispersed in 
HPMCAS and HPMCP matrices. HPMCP based solid dispersions are susceptible to instability 
due to poor process-ability of EFZ in the matrix. The solid dispersions of EFZ in HPMCAS 
matrices exhibited enhanced dissolution rates, attributed to the intermolecular interactions 
resulting in inhibition of crystallization and increased wettability. The combination of melt 
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extrusion and Hypromellose ester derivatives successfully resulted in amorphous solid dispersion 
systems with enhanced solubility of EFZ. This study demonstrates that Hypromellose ester 
derivatives formulation of EFZ via HME may be effective for other poorly soluble drugs. 
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CHAPTER - 5 
DEVELOPMENT AND CHARACTERIZATION OF TASTE MASKED 
FORMULATIONS OF EFAVIRENZ UTILIZING HOT MELT EXTRUSION 
5.1. ABSTRACT 
The objective of this study was to formulate taste-masked pellets and tablets of EFZ with 
Eudragit
®
 E PO as the matrix polymer utilizing hot melt extrusion (HME) technology. The 
drug/polymer physical mixtures were extruded as rods with a co-rotating twin-screw extruder 
and then pelletized. The chemical interaction between EFZ and Eudragit
®
 E PO was determined 
using Fourier transform infrared (FTIR) spectroscopy. Solid-state characterization of EFZ in the 
Eudragit
®
 E PO matrix was carried out using differential scanning calorimetry (DSC), Powder 
X-ray Diffraction (PXRD) and Scanning electron microscopy (SEM) techniques. The solubility 
of EFZ was improved significantly due to its conversion into a more water-soluble amorphous 
form. Drug load had a significant effect on EFZ release characteristics from the pellets. In vitro 
release profiles obtained with the extruded pellets at pH 6.8 (simulated salivary medium) 
indicated that EFZ release would be extremely limited in the saliva, unlike the physical mixture, 
thus avoiding irritation of the oral mucosa (BMS, burning mouth syndrome). More than 90% 
drug release in 30minutes was observed in simulated gastric medium (pH 1.2) with the extruded 
pellets. The dissolution rate of EFZ from the melt extruded pellets was faster than that from the 
physical mixtures at all drug loads (p<0.05) in simulated gastric medium. Taste masked EFZ 
pellets were thus successfully developed without affecting the dissolution rate in simulated 
gastric medium. 
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Keywords: Hot melt extrusion (HME), Eudragit
®
 E PO, EFZ, differential scanning calorimetry 
(DSC), Powder X-ray diffraction (PXRD), Fourier transform Infrared (FTIR), Scanning electron 
microscopy (SEM). 
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5.2. INTRODUCTION 
EFZ is an approved first choice HIV-1 reverse transcriptase inhibitor recommended by the 
World Health Organisation (WHO) for the treatment of children above the age of 3 (39). It is a 
crystalline, non-hygroscopic and lipophilic (log P of 5.4) material with an aqueous solubility of 
9.2 µg/mL (pH 8.7) at 25 ºC (40). The extremely low aqueous solubility of the drug leads to 
limited oral absorption and low bioavailability (40-45%) (41). The inter- and intra-individual 
variability is found to be relatively high being approximately 55-80% and 19-24%, respectively 
(41). Another drawback of EFZ treatment is that it irritates the oral mucosa, causing a burning 
mouth syndrome (BMS). BMS is one of the main causes of unplanned interruption in pediatric 
treatment (39). It causes vomiting and spitting which might result in EFZ’s under-dosing and 
erratic plasma concentrations due to the partial intake of the administered dose. There have been 
attempts in the literature to enhance the solubility of EFZ with cyclodextrins (40), surface-
modified polypropylene imine (PPI) dendrimers (42), encapsulation within polymeric micelles of 
linear and branched poly(ethylene oxide)-polypropylene oxide block copolymer (42).
 
However, 
the scale-up of these formulations is limited by the many discontinuous steps. HME is a 
continuous process and requires fewer operator interventions and can thus yield improved 
product quality. HME technology has become easier for the industry to adopt, due to the 
technical developments of recent years i.e., extruder vendors have begun to produce units 
designed according to the principles of good manufacturing practice (43). 
Hot melt extrusion (HME) technology has become popular for taste masking of bitter drugs, 
besides its solubility enhancement capabilities, by producing solid dispersion that prevent drugs 
from coming into direct contact with the patient’s taste buds (44). Eudragit® E PO is a cationic 
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copolymer based on dimethylaminoethyl methacrylate and is soluble at a pH below 5.5 (Figure 
5-1). This polymer can thus prevent the release of the drug in the saliva (pH 6.8–7.4) while 
readily dissolving in the gastric ﬂuids (pH 1.0–1.5). Hence, Eudragit® E PO is a suitable matrix 
for taste masking poorly soluble solid dosage forms. In this study, a co-rotating twin screw 
extruder with a screw diameter of 16 mm and a barrel length of 640 mm was used. The length of 
the screws in the extruder is given in terms of length of the screw to the screw diameter (L/D) 
ratio, which in this case is 40:1. The extruder consists of two screws which are assembled with 
the standardized screw elements, conveying and kneading elements (Figure 1). The conveying 
elements are installed at the beginning and end of the extruder working jointly to transport the 
melted material to the die plate. The kneading elements have various angles and produce higher 
mixing and shearing. The twin screw variables, for example screw design, barrel layout, screw 
speed directly affect the process parameters like shear rate, residence time, dispersion of drug in 
polymeric matrix and color of extrudates  
The goal of the present study was to develop and characterize stable, taste masked, hot melt 
extruded oral pellet formulations of EFZ utilizing various drug: polymer ratios. Multi-particulate 
oral dosage forms like pellets offer several advantages over monolithic systems (e.g. tablets). 
The pellets pass through the stomach pylorus rapidly and disperse homogeneously in the gastro-
intestinal tract, independently of gastric emptying and feeding state, which minimizes inter and 
intra subject variability. Thus, the pellet formulations can be helpful in improving inter- and 
intra-individual variability associated with EFZ (14). Importantly, these pellet formulations will 
allow flexibility of dosing and taste masking of EFZ for pediatric patients. The multiple unit 
dosage form (pellets) offers a flexible dosing system for pediatric patients (45). Since each 
individual unit contains a small amount of drug, the dose can be easily adjusted by measuring a 
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specific weight, or counting the required number of pellets, depending on the patient’s body 
weight. Secondly, pellets also offer an advantage in that they can be sprinkled on food, mixed 
with fluids (water, milk or jelly) or directly swallowed, improving pediatric patient compliance 
(45).  
 
Eudragit
® 
EPO 
Figure 5-1: Structure of Eudragit
® 
EPO. 
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5.3. MATERIALS 
The following materials were used as supplied: Efavirenz (Ria International, East Hanover, NJ), 
Eudragit
®
 E PO (E PO, Evonik Industries, Germany). Sodium lauryl Sulphate (SLS), Sodium 
phosphate monobasic (NaH2PO4; M.W 119.98 g/mol), Sodium phosphate dibasic (Na2HPO4; 
M.W 141.96 g/mol) and Hydrochloric acid were obtained from Spectrum Chemical, Inc., 
Gardena, CA. The solvents acetonitrile (HPLC grade) and methanol (HPLC grade) were 
purchased from Fisher Chemicals, NJ. HPLC grade water was freshly prepared in the laboratory 
by Nanopure system (Barnstead, Dubuque, IA). 
5.4. METHODS 
5.4.1. HOT-MELT EXTRUSION 
EFZ and Eudragit
®
 E PO were mixed in various drug loads (10, 25, 50, 60 and 70% w/w) in a V-
cone blender (MaxiBlendTM, GlobePharma) at 25 rpm for 15 minutes and then extruded into 
uniform rods with a co-rotating twin screw extruder (16 mm Prism EuroLab, ThermoFisher 
Scientific) at an extrusion temperature range of 70-110 °C and a screw speed of 70 rpm (Table 5-
1). The feed rate was adjusted so that the % Torque was at approximately 60 % for optimum 
performance. The diameter of the extruded rods was approximately 2 mm. These extrudates were 
subsequently processed into pellets of 1 mm thickness using a pelletizer (Type L-001-9482, 
Thermoscientific, Stone, UK). The extrudates were pulverized using a sieve mesh size “20” 
according to US ASTM standards in a comminuting mill (FITZPATRICK
®, Model “L1A”). The 
milled extrudates (HME) were further blended with tablet excipients as shown in Table 5-2. The 
tablets were prepared with physical mixtures (Phy. Mix) by blending the excipients while 
maintaining the composition identical to their corresponding HME tablets. The hot melt extruded 
EFZ tablets and their corresponding physical mixture tablets were compressed using a MTP 1 
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tablet press equipped with an 8mm round beveled edge punch. The tablets (240±0.26, 472±0.63 
and 942±0.65 mg) equivalent to 50, 100, 200 and 400 mg of EFZ content were produced. 
Table 5-1 Processing temperatures for the formulations 
 
 
Zone 
10 
Zone 
9 
Zone 
8 
Zone 
7 
Zone 
6 
Zone 
5 
Zone 
4 
Zone 
3 
Zone 
2 
Zone 
1 
Zone 
110 110 120 120 110 110 100 90 80 70 °C 
 
Feed 
 97 
5.4.2. THERMOGRAVIMETRIC ANALYSIS (TGA) 
TGA (Perkin Elmer Pyris 1 TGA equipped with Pyris software) analysis of Eudragit
®
 E PO, 
EFZ and physical mixtures (Phy.Mix) with various drug: polymer ratio was studied within 
temperature range of 30-200 °C at a heating rate of 20 °C/min. The thermal stability of drug and 
polymer was determined as a function of weight loss. 
5.4.3. DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
Perkin-Elmer Pyris 1 DSC, equipped with Pyris Manager Software, was used to study the solid-
state characteristics of EFZ in Eudragit
®
 E PO matrix, pre-extrusion physical mixtures and 
extruded pellets. All samples were weighed approximately 8–10 mg, hermetically sealed in an 
aluminum pan and heated from -10 °C to 180 °C at a linear heating rate of 10°C/min. 
5.4.4. SOLUBILITY PARAMETER 
Solubility parameter calculations were performed using Molecular Modeling Pro software 
(Chem SW Inc., Fairfield, CA) utilizing group contribution approaches (Molecular Modelling 
Pro., 2006). 
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5.4.5. FOURIER TRANSFORM INFRARED (FTIR) SPECTROSCOPIC ANALYSIS 
FTIR studies were undertaken to detect the possible interactions between EFZ and Eudragit
®
 E 
PO in the solid dispersions. FTIR spectra for the EFZ and Eudragit
®
 E PO were obtained using a 
Perkin-Elmer spectrometer (Perkin-Elmer Life and Analytical Sciences, Shelton, CT, USA). A 
spectrum was collected for each sample within wave number region 4,000–650 cm−1. Samples of 
EFZ in Eudragit
®
 E PO, physical mixtures and pellets with various drug loads (10, 25, 50, 60 and 
70% w/w) were weighed such that they contained an equivalent amount of EFZ in all the 
samples. The spectrums were analyzed for the absence or shift in the wave numbers of the 
characteristic peaks. 
5.4.6. POWDER X-RAY DIFFRACTION (PXRD) 
Crystallinity of EFZ in the hot-melt extruded pellets and their respective physical mixtures were 
analyzed using X-ray diffractometry. The studies were performed on a D-8 Advance X-ray 
diffractometer (Bruker-Axs) equipped with Diffrac Plus1 software. The generator operating 
voltage and current were 40 kV and 40 mA, respectively. The step size was 0.01º and the dwell 
time at each step was 1 sec. The scanning speed was 2ºper min, and the 2 Theta scanning range 
was from 5º to 40º. 
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5.4.7. SCANNING ELECTRON MICROSCOPY (SEM) ANALYSIS 
The morphology of amorphous EFZ in the pellets was compared against the physical appearance 
of the pure drug utilizing a scanning electron microscope. The samples were mounted onto an 
aluminum stage using adhesive carbon tape. Samples were then sputter coated with gold under 
an argon atmosphere using a Hummer™ 6.2 Sputter Coater (Ladd Research Industries, Williston, 
VT, USA) in a high vacuum evaporator equipped with an omnirotary stage tray to produce 
uniformly coated specimens. The processed samples were examined and the images were 
captured using a JEOL JSM-5600 scanning electron microscope (JEOL USA, Inc., Waterford, 
VA, USA) operating at an accelerating voltage of 9–13 kV. 
5.4.8. CHROMATOGRAPHIC CONDITIONS 
A Waters HPLC-UV system (Waters Corp, Milford, MA) and a Symmetry Shield RP C-18 
(250×4.6 mm, 5 μm) column was used at a detection wavelength of 245 nm. The mobile phase 
consisted of acetonitrile and water (0.1% v/v Formic acid, pH=4) at a ratio of 60:40 (v/v). The 
mobile phase flow rate was maintained at 1.5 ml/min. EFZ retention time was 7.2±0.43 min 
under these conditions. Injection volume was 20 μl. The HPLC data was analyzed using 
Empower 2 software. 
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5.4.9. SOLUBILITY STUDIES 
The solubility of pure drug, physical mixtures and pellets with various drug: polymer ratios (10, 
25, 50, 60 and 70% w/w) was determined following the standard shake flask method, wherein 
excess quantities were added to 50 ml of water, freshly prepared dissolution medium 0.2% SLS 
in 0.1M HCL (pH 1.2, simulated gastric medium) and 0.2% SLS 0.2M sodium phosphate buffer 
(pH 6.8, simulated salivary medium). To achieve uniform mixing, samples were continuously 
agitated at 100 rpm at 37 °C, separately, for a period of 24 hour in a reciprocal shaking water 
bath (Fisher Scientific, USA). At the end of 24 hour, samples were centrifuged (Centrifuge 
5415R, eppendorf, USA) at 10,000 rpm for 10 minutes; the clear supernatant was suitably 
diluted and analyzed for drug content. 
5.4.10. IN VITRO RELEASE STUDIES 
In vitro release studies were performed according to USP 31 apparatus I using discriminatory 
dissolution medium comprised of 1000 ml of 0.2% SLS in 0.1M HCL (pH 1.2, simulated gastric 
medium) and 0.2% SLS in 0.2M sodium phosphate buffer (pH 6.8, simulated salivary medium). 
Hanson SR8-plus™ dissolution test station (Chatsworth, CA) was used at 37±0.5 °C and paddle 
speed was maintained at 50 rpm. Samples were collected at predetermined time intervals, 
through a stainless steel cannula with a 0.2 µm nylon filter tip attached to a 1 ml syringe. These 
samples were analyzed using HPLC/UV. The results were reported as the average of 3 replicates 
± SD. Dissolution profiles were compared using similarity factor (f2). An f2 value larger than 50 
indicates that the two dissolution profiles are similar. 
 101 
5.4.11. STABILITY STUDIES 
The impact of temperature and humidity conditions on the physical and chemical stability of 
EFZ in the pellets and tablets were determined in HDPE bottles at 4 °C, 25 °C/60% RH, 40 
°C/75% RH and 60 °C. The dissolution profiles, chemical and physical stability of the pellets 
were examined at initial, 1, 3 and 6 month time points. The dissolution profiles of pellet 
formulations at different time points were compared using the f2 similarity factor. 
5.4.12. DATA ANALYSIS 
In all the cases, statistical analysis was performed utilizing one-way analysis of variance. A 
statistically significant difference was considered when p<0.05. 
Table 5-2: Tablet formulation used in vitro release studies. 
S. No.  Function % w/w 
1 
Extruded milled powder/Physical 
mixtures  
API carrier 85 
2 Microcrystalline Cellulose  
Dispersing 
agent 
6 
3 Silicon dioxide  Anti-adherent 1 
4 Xylitol 
Sweetening 
Agent 
3.5 
4 Sodium Coscarmellose  
Super-
disintegrant 
7 
6 Sodium Stearyl Fumarate Lubricant 0.5 
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5.5. RESULT AND DISCUSSION 
5.5.1. HOT MELT EXTRUSION 
The solubility parameters of EFZ and Eudragit
®
 E PO were calculated to be 24.5 and 19.6 
MPa
1/2
, respectively. The difference in the solubility parameters (∆δt) is 4.9 MPa
1/2
, which is 
lower than the maximum value of 7 MPa
1/2 
required for the polymer–drug miscibility indicating 
that EFZ would likely be miscible with Eudragit
®
 E PO. The percent drug load had a significant 
effect on the appearance of the extruded pellets. The extruded pellets were clear and transparent 
up to 60%w/w drug load. When all the EFZ dissolves in the Eudragit
®
 E PO matrix during 
extrusion a homogenous solution is formed. This solution upon cooling forms a solid solution. 
The transparent characteristic of the extrudates, obtained with the 10, 25, 50 and 60% w/w EFZ 
loads, signifies the formation of a homogenous miscible system upon cooling. The turbid 
extrudates obtained with the 70% w/w EFZ indicates solid dispersion formation that is not 
chemically and physically uniform throughout or comprises of more than one phase. This could 
presumably be due to the fact that not all of the EFZ has dissolved in the polymer phase (46).  
5.5.2. THERMAL ANALYSIS 
TGA has frequently been used to assess the thermal stability of drugs and excipients/polymers 
prior to HME. When heated from 30 °C to 350 °C at a rate of 20 °C/min, less than 2% 
degradation below 200 
°
C was observed with the pure drug and physical mixture at the various 
drug: polymer ratio (Figure 5-2). Additionally, TGA confirmed the thermal stability of Eudragit
®
 
E PO at the extrusion temperatures used. 
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Figure 5-2: Thermal gravimetric analysis (TGA) of Eudragit
® 
EPO and EFZ at various drug 
loads. 
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DSC analysis of crystalline EFZ showed a single sharp endothermic peak within the temperature 
range of 137.54± 0.7 °C with ∆Hf=51.1±2 Jg
–1
. Quench-cooled EFZ exhibited a glass transition 
temperature of 34.45 ± 2.1 °C (onset Tg) and no other exothermic peak of crystallization or 
endothermic peak of melting was observed (Figure 3-4). A variety of pharmaceutical glass 
formers or drugs with high Tm/Tg (Kelvins) ratios generally crystallize more rapidly in solid 
dispersions than drugs with low Tm/Tg values at a given drug load and temperature (47). The 
Tm/Tg ratio of EFZ is 1.32, a somewhat high value, which indicates formulation with drug load 
>50% w/w will be needed to ensure sufficient physical stability (48). 
A melting endotherm for EFZ was not observed in the physical mixtures containing 10 to 50% 
w/w of EFZ indicating that the drug is completely soluble in Eudragit
®
 E PO at these 
concentrations (Figure 5-3 a). In contrast to physical mixtures the pellets containing up to 60% 
w/w drug load did not show the EFZ melting endotherm (Figure 5-3 b). However, the pellet 
formulations at 70% w/w drug load exhibited a Tg and a diffused endothermic peak around 120 -
135 °C indicating partial crystallization of EFZ out of the Eudragit
®
 E PO matrix at this 
concentration. 
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Figure 5-3: Thermal properties of physical mixtures and extruded pellets. a. EFZ melting 
endotherms in the physical mixtures was observable in weight proportions >60% w/w. 
 
a 
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b. The melting endotherm was not observed in extruded pellets <70% w/w. 
5.5.3. FTIR Spectroscopy 
FTIR spectroscopy has been successfully used for exploring the differences in molecular 
conformations, crystal packing and hydrogen bonding arrangements of organic compounds. 
Spectral variations originate due to alteration in bonds that exhibit characteristic vibrational 
frequencies, leading to frequency shifts and splitting in absorption or transmittance of peaks. 
Chemical interactions between EFZ and Eudragit
®
 E PO in the solid dispersions may stabilize 
the amorphous state of EFZ. Also, taste masking can be achieved through intermolecular forces 
(e.g., hydrogen bonding and/or ionic interaction) between the active substance and polymer 
matrix. There are several reports in the literature of potential interaction of Eudragit
®
 E PO with 
drugs (49). EFZ (pka=9.1) is considered to be a weak acid (50) whereas Eudragit
®
 E PO is a 
cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and 
b 
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methylmethacrylate. EFZ crystals show characteristic bands at 3311.33 cm
-1
, 2249.86 cm
-1
, 
1602.29 cm
-1
, 1745.42 cm
-1
, 1241.11 cm
-1
 and 1316.13 cm
-1
 attributed to N-H stretching 
vibrations, aromatic C-H stretching vibration, C≡C stretching vibration, C=O stretching 
vibration, C-F stretching vibration, C-O-C stretching vibration, respectively. The bands 
corresponding to C=O vibrations and N–H stretching, at 1728.69 cm-1 and 3260.09 cm-1, 
respectively, became broadened and diffused in the case of the amorphous EFZ (Figure 5-4 a). 
The spectra suggests the participation of –NH and C=O groups in intermolecular hydrogen 
bonding between EFZ molecules in the amorphous state. The spatial arrangement of EFZ 
molecules in the crystal lattice does not allow intermolecular hydrogen bonding which starts to 
occur once the orderliness of crystalline lattice is disturbed due to the formation of the 
amorphous form. However, these intermolecular hydrogen bonds are relatively weak and the 
amorphous form tends to revert back to the crystalline form (51). 
Eudragit
®
 E PO shows the characteristic bands of the ester groups at 1150-1190 cm
-1
, 1239.23 
cm
-1
 and 1268.22 cm
-1
, as well as the C=O ester vibration at 1722.79 cm
-1
. The absorptions at 
2770.23cm
-1
 and 2821.82cm
-1
 can be assigned to the dimethylamino groups. The physical 
mixtures of EFZ in Eudragit
®
 E PO showed a summation of the EFZ and Eudragit
®
 E PO IR 
spectra. In the extruded pellets containing EFZ and Eudragit
®
 E PO matrix, the band at 3311.33 
cm
-1
 corresponding to N-H stretching in crystalline EFZ spectra disappeared and the C=O 
stretching vibration at 1745.42 cm
-1
 shifted to higher wave numbers i.e. 1755-1758 cm
-1
(Figure 
5-4 a-d). Moreover, the bands corresponding to dimethylamino groups in Eudragit
®
 E PO at 
2770.23 cm
-1
 and 2821.82 cm
-1
 exhibited decreased intensity in the extruded pellets (Figure 6 b-
d). Since dimethylamino group is a proton-accepting functional group, the proton-donating 
carboxyl group of EFZ formed an intermolecular bond with the dimethylamino group of 
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Eudragit
®
 E PO exhibiting a band shift was observed in the spectra. The extruded pellet 
formulations containing 70% w/w EFZ in Eudragit
®
 E PO matrix showed a summation of the 
individual components of the IR spectra similar to the physical mixture (Figure 5-4 e). The 
characteristic bands at 3311.83 cm
-1
 corresponding to N-H stretching and 1744.61 cm
-1
 
corresponding C=O stretching vibration were observed indicating the presence of crystalline 
EFZ in the hot melt extruded pellet formulations containing 70% w/w EFZ. This data suggest 
that EFZ is not completely soluble at this concentration in the Eudragit
®
 E PO matrix (Figure 5-4 
e). 
Satigrahi et al, investigated the formation of amorphous EFZ with Plasdone
®
 S-630 and 
Eudragit
®
 E PO systems (1:1) utilizing a small scale extruder (HAAKE Minilab series) (52). 
According to their studies, EFZ and Eudragit
®
 E PO extrudates do not exhibit any specific 
interaction under the processing conditions used. The observed differences could be because of 
variation in mixing efficiency of the instruments. In the present study, a co-rotating twin screw 
extruder with ten heating zones, three mixing zones and a large screw diameter of 16 mm was 
used. This extruder generates higher shear and achieves dispersion at the molecular level which 
is not possible with micro compounders such as HAAKE Minilab (Figure 1). The extruder screw 
design pays crucial role in the dispersion of drug within the polymer matrix. Therefore, the 
intermolecular interaction of drug with polymer could vary depending on the extruder design. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Crystalline Efavirenz
Amorphous Efavirenz
Eudragit® E PO
10% Efavirenz in Eudragit® E PO Phy. Mix
10% Efavirenz in Eudragit® E PO extruded
3311.33 2249.86
1745.42
1602.29
1495.26
3260.09
2249.05
1728.69
1601.35
1495.93
1402.05
2949.18
2821.82
2770.23
1722.79
1456.62
1388.11
2948.52
2768.93
1723.85
1451.92
1387.97
2949.89
1720.19
1451.31
 
Figure 5-4: An overlay of FTIR spectra of Crystalline EFZ, amorphous EFZ and Eudragit
®
 E 
PO at various drug loads a. 10% w/w EFZ in Eudragit
® 
EPO matrix, 
¯NH 
¯C=O 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Crystalline Efavirenz
Amorphous Efavirenz
Eudragit® E PO
25% Efavirenz in Eudragit® E PO Phy.Mix
25% Efavirenz in Eudragit® E PO extruded
3311.33 2249.86
1745.42
1602.29
1495.26
3260.09
2249.05
1728.69
1601.35
1495.93
1402.05
2949.18
2821.82
2770.23
1722.79
1456.62
1388.11
3311.06
2949.33
2770.51
2250.22
1724.21
1602.67
1456.36
1388.60
2950.73
2250.29
1758.22
1723.54
1456.71
 
b. 25% w/w EFZ in Eudragit
®
 E PO matrix,  
¯C=O 
¯NH 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Crystalline Efavirenz
Amorphous Efavirenz
Eudragit® E PO
50% Efavirenz in Eudragit® E PO Phy.Mix
50% Efavirenz in Eudragit® E PO extruded
3260.09
2249.05
1728.69
1601.35
1495.93
1402.05
2949.18
2821.82
2770.23
1722.79
1456.62
1388.11
3313.72
2949.62
2249.65
1727.69
1602.51
1495.23
1396.12
2950.69
2249.53
1755.52
1726.05
1601.91
3311.33 2249.86
1745.42
1602.29
1495.26
 
c. 50% w/w EFZ in Eudragit
®
 E PO matrix, 
¯C=O 
¯NH 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Crystalline Efavirenz
Amorphous Efavirenz
Eudragit® E PO
60% Efavirenz in Eudragit® E PO Phy.Mix
60% Efavirenz in Eudragit® E PO extruded
3260.09
2249.05
1728.69
1601.35
1495.93
1402.05
1329.69
2949.18
2821.82
2770.23
1722.79
1456.62
1388.11
3312.87
2948.85
2249.90
1743.57
1602.22
1494.97
2952.44
2249.78
1756.58 1725.05
1601.67
1493.05
1453.45
1402.29
3311.33 2249.86
1745.42
1602.29
1495.26
1316.13
 
d. 60% w/w EFZ in Eudragit
®
 E PO matrix 
¯C=O 
¯NH 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Crystalline Efavirenz
Amorphous Efavirenz
Eudragit® E PO
70% Efavirenz in Eudragit® E PO Phy.Mix
70% Efavirenz in Eudragit® E PO extruded
3311.33 2249.86
1745.42
1602.29
1495.26
1316.13
3260.09
2249.05
1728.69
1601.35
1495.93
1402.05
1329.69
3313.19
2948.52 2250.01
1743.34
1602.13
1494.91 1316.13
3312.83
2952.25
2249.50
1744.61
1601.72
1494.88
2949.18
2821.82
2770.23
1722.79
1456.62
1388.11
 
e. 70% w/w EFZ in Eudragit
®
 E PO matrix. 
 
¯C=O 
¯NH 
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5.5.4. POWDER X-RAY DIFFRACTION (PXRD) 
Crystalline EFZ PXRD pattern comprises of 2 Theta values of 6.8±0.2, 10.3±0.2, 10.8±0.2, 
14.1±0.2, 16.8±0.2, 20.0±0.2, 20.5±0.2, 21.1±0.2 and 24.8±0.2 (34). The patterns for EFZ, 
physical mixtures, and HME pellets are represented in the Figure 5-5. There were no crystalline 
peaks corresponding to EFZ in the HME pellets up to 60% w/w drug load indicating EFZ existed 
in an amorphous state within the HME pellets. However, crystallization of EFZ was observed 
within HME pellets containing 70% w/w EFZ (peaks corresponding to 6.8±0.2 and 24.8±0.2). 
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Figure 5-5: PXRD patterns of hot melt extruded pellets and physical mixtures with 10, 25, 50, 
60 and 70% w/w drug load. (Arrows indicate the characteristic 2 theta values of EFZ). 
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5.5.5. SCANNING ELECTRON MICROSCOPY (SEM) ANALYSIS 
SEM has been demonstrated to be a highly sensitive method for the detection of drug crystals at 
the surface of extruded formulations (9, 16). The micrographs (Figure 5-6 a–f) represent pure 
drug and the surface of the hot-melt extruded pellets. Pure EFZ exists predominantly as broken 
and fused needles (53) whereas in the melt extruded pellets containing 60% w/w EFZ it appeared 
as amorphous aggregates. EFZ crystals were seen embedded on the surface of pellets as well as 
irregular aggregates indicating existence of drug in more than one phase in the polymer matrix 
containing 70% w/w EFZ (Figure 5-6 f). 
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a  b   
c  d   
e  f  
Figure 5-6: a. SEM of pure EFZ viewed at 1,000 X magnification b. The surface of hot-melt 
extruded pellets matrix 10% w/w EFZ in Eudragit
®
 E PO matrix c. The surface of hot-melt 
extruded pellets matrix 25% w/w EFZ in Eudragit
®
 E PO matrix d. The surface of hot-melt 
extruded pellets matrix of 50% w/w EFZ in Eudragit
® 
EPO matrix e. The surface of hot-melt 
extruded pellets matrix of 60% w/w EFZ in Eudragit
®
 E PO matrix and f. The surface of hot-
melt extruded pellets matrix of 70% w/w EFZ in Eudragit
®
 E PO matrix. 
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5.5.6. IN VITRO RELEASE STUDIES  
The aqueous solubility of EFZ at 37 °C was found to be 5.26±2.3 µg/ml. The saturation 
solubility of EFZ at 37°C in 0.2% SLS 0.2M sodium phosphate buffer (pH 6.8, simulated 
salivary medium) and 0.2% SLS in 0.1M HCL (pH 1.2, simulated gastric medium) was found to 
be 212.26±3.32µg/ml and 232.47±4.35 µg/ml, respectively. The pellet formulations containing 
various drug: polymer ratios, meeting the desired post extrusion drug content (98.36±0.47% 
w/w), were tested for drug release. Dissolution testing was employed to assess the in vitro taste 
masking ability of the hot melt extruded pellet formulations. The pH of the saliva has been 
reported to be between 6.8- 7.4 and delay in drug release at this pH of even only a few minutes 
can prevent the unpleasant taste sensation or in the present case, irritation of the oral mucosa 
(BMS, burning mouth syndrome). The release profiles, obtained with melt extruded pellets in 
simulated salivary medium indicate that release will be delayed in simulated salivary medium the 
hot melt extruded pellets with 10, 25 and 50% w/w drug load (Figure 5-7). Hence, the hot melt 
extruded pellets will provide sufficient taste masking and prevent the BMS. In contrast to the 
release profile in simulated salivary medium, the hot melt extruded pellet formulations rapidly 
released EFZ in simulated gastric medium. Also, the dissolution rate of the melt extruded pellets 
was faster than that of the physical mixtures (p<0.05, Figure 5-8) in simulated gastric medium. 
For example, 90% drug was released within 30minutes from the hot melt extruded pellets 
consisting of 10, 25 and 50% w/w drug load in simulated gastric medium. However, with the 
physical mixtures only 25-30% dissolution took place in 60 minutes. The observed dissolution 
rate enhancement in simulated gastric medium was due to the conversion of EFZ into an 
amorphous state, which offers a low thermodynamic barrier to solution, and also due to 
Eudragit
®
 E PO’s solubilizing effect at acidic pH (Figure 5-8).  
 119 
The pellets containing 60 and 70% w/w EFZ exhibited significantly lower drug release in 
simulated gastric medium in comparison to pellets from 10, 25 and 50% w/w drug load (f2<50). 
For example, less than 70% drug release occurred in 60 minutes with the 60 and 70% w/w drug 
loaded melt extruded pellets with in comparison to 100% drug release in less than 60minutes 
from the hot melt extruded pellets with 10, 25 and 50% w/w drug load. The pellets with 25 and 
50% w/w drug load exhibited release profiles similar to that of the marketed formulation of EFZ 
(micronized and formulated with SLS containing 50 mg EFZ) under the same dissolution 
conditions (f2>50, Figure 5-9). EFZ has a usual daily adult dose of 600 mg and the recommended 
daily doses in children are between 200 mg and 600 mg (39, 54). Therefore, in the present 
studies pellets with 25 and 50% w/w drug load were selected for further stability studies. These 
pellets were used to formulate the tablets (Figure 5-10 to 5-13). 
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Figure 5-7: Release profile of hot melt extruded pellets and physical mixtures with 10, 25, 50, 
60 and 70% w/w drug load equivalent to 200 mg EFZ in pH 6.8 buffer with 0.2% SLS. 
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Figure 5-8: Release profile of hot melt extruded pellets and physical mixtures with 10, 25, 50, 
60 and 70% w/w drug load equivalent to 200 mg EFZ in 0.1MHCL with 0.2% SLS. 
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Figure 5-9: Comparison of the release profiles of the 25%w/w and 50%w/w hot melt extruded 
pellets and physical mixture equivalent to 50 mg with that of marketed formulation 50 mg EFZ. 
capsules. 
 
Figure 5-10: In vitro release profiles of EFZ tablet weight a 240 mg (Dose=50 mg EFZ) and b 
and 472 mg (Dose=100 mg EFZ) with HME and Phy. Mix with 25% EFZ in Eudragit
®
 E PO 
a 
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matrix (Dissolution conditions: USP type II, 50 RPM, 1000 ml with 0.2% SLS in pH 1.2 or 6.8 
buffer at 37 ºC). 
 
Figure 5-11: In vitro release profiles of EFZ tablet weight a 240 mg (Dose=50 mg EFZ) and b 
and 472 mg (Dose=100 mg EFZ) with HME and Phy. Mix with 25% EFZ in Eudragit
®
 E PO 
matrix (Dissolution conditions: USP type II, 50 RPM, 1000 ml with 0.2% SLS in pH 1.2 or 6.8 
buffer at 37 ºC). 
b 
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Figure 5-12: In vitro release profiles of EFZ tablet weight a 240mg (Dose=100 mg EFZ) and b 
472 mg (Dose=200 mg EFZ) with HME and Phy. Mix with 50% EFZ in Eudragit
®
 E PO matrix 
(Dissolution conditions: USP type II, 50 RPM, 1000 ml with 0.2% SLS in pH 1.2 or 6.8 buffer at 
37 ºC). 
a 
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Figure 5-13: In vitro release profiles of EFZ tablet weight a 240 mg (Dose=100 mg EFZ) and b 
472 mg (Dose=200 mg EFZ) with HME and Phy. Mix with 50% w/w EFZ in Eudragit
®
 E PO 
matrix (Dissolution conditions: USP type II, 50 RPM, 1000 ml with 0.2% SLS in pH 1.2 or 6.8 
buffer at 37 ºC). 
5.5.7. STABILITY STUDIES 
The 6 month stability study data for pellet formulations with 25 and 50% w/w drug load suggests 
that the formulation was physically and chemically stable. The % EFZ content remaining in the 
pellet formulations was greater than 97.5%±0.63, and the drug release profile remained 
unchanged (f2 > 50) after 6 month storage at 40 °C/75% RH (Figure 5-14). EFZ melting peak 
was not detected by DSC even after 6 month storage at 40 °C/75% RH (Figure 5-15). The 
observed stability of the amorphous form of EFZ could be due to its interaction with Eudragit
®
 E 
PO. 
b 
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Figure 5-14: Release profiles of 25% w/w and 50% w/w hot melt extruded pellets at the initial, 
1, 3 and 6 month time points following storage at 40 °C/75% RH. 
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Figure 5-15: DSC thermogram illustrating stability of amorphous form of EFZ in Eudragit
®
 E 
PO matrix hot melt extruded pellets at the initial,1, 3 and 6 month time points following storage 
at 40 °C/75% RH. 
5.6. CONCLUSION 
Hot-melt extrusion is a simple, efficient, and continuous process and has been used in this study 
to produce immediate-release EFZ pellet formulations. The solid state characteristics of EFZ in 
the pellets were confirmed using DSC, PXRD and SEM. The dissolution rate of EFZ was 
significantly improved in simulated gastric medium with HME technology using Eudragit
®
 E 
PO. In vitro release profile in simulated salivary medium confirmed the ability of the Eudragit
®
 
E PO to minimize the release of EFZ in the saliva. This will prevent the BMS caused by 
ingestion of EFZ. The pellet formulation will improve pediatric patient compliance not only by 
taste masking but also by providing flexibility of dosing. Since each pellet contains a specific 
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amount of drug; the drug dose can be easily adjusted by measuring a specific weight of pellets 
depending on the patient’s body weight. The administration of pellets is easier in pediatric 
patients as it can be sprinkled on food, mixed with fluids (water, milk or jelly) or directly 
swallowed. EFZ exhibited adequate physical stability probably due to the intermolecular 
interactions with the dimethylamino group of Eudragit
®
 E PO. The dissolution profile remained 
unchanged even after 6 months storage at 40°C/75% RH. The release from melt extruded pellets 
with drug loads 10, 25, 50% w/w was comparable to that of a marketed formulation, which 
released 100% drug in less than 60 minutes. This study illustrates that HME could be considered 
as an alternative technology for improving the dissolution characteristics as well for taste 
masking of EFZ to improve pediatric patient compliance. 
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CHAPTER - 6 
SUGAR ALCOHOLS AS CARRIERS FOR SOLID DISPERSIONS USING MELT 
EXTRUSION TECHNIQUES 
6.1 ABSTRACT 
Hot melt extrusion (HME) technology has become very popular in generation of amorphous 
solid dispersions of poorly soluble drugs for attainment of increasingly popular immediate 
release dosage forms. Water-soluble carriers such as sugar alcohols (Mannitol, Sorbitol, and 
Xylitol) have recently attracted considerable interest as a means of improving the dissolution 
rate, and hence potential for increased bioavailability of hydrophobic drugs. However, their 
utility as a primary matrix in melt extrusion has not been studied. Therefore, the present work 
focuses on the formulation of the poorly water soluble drug Carbamazepine (CBZ) using sugar 
alcohols as carriers. In all samples, the amorphous structure of CBZ was confirmed using 
differential scanning calorimetry (DSC) and Powder X-ray diffraction (PXRD). Also, all of the 
investigated drug/sugar alcohol combinations demonstrated improved solubility and dissolution 
rates. The increase in dissolution rates was attributed to the presence of the CBZ in its 
amorphous form. 
Keywords: Hot melt extrusion, Sugar alcohols, Carbamazepine, differential scanning calorimetry 
(DSC), Powder X-ray diffraction. 
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6.2. INTRODUCTION 
A sugar alcohol (also known as a polyol, polyhydric alcohol, or polyalcohol) is a hydrogenated 
form of carbohydrate, whose carbonyl group (aldehyde or ketone, reducing sugar) has been 
reduced to a primary or secondary hydroxyl group (55). Sugar alcohols or Polyols are sugar-free 
sweeteners. Some of them are found naturally in various fruits and vegetables. Sugar alcohols 
may be used either as sweeteners or as fillers i.e. non-sweetening functions in the food industry 
or pharmaceuticals. The most widely used polyols are Sorbitol, Mannitol, Maltitol, Isomalt, 
Lactitol, Xylitol and Erythritol (55). 
Sugar alcohols are very useful in formulating solid dosage forms such as tablets, capsules, and 
granules. Sorbitol powder with its characteristic sweet and cool taste is ideally suited for oral 
medication such as suckable tablets. Mannitol in various forms (spray dried, directly 
compressible and granulated) is used for chewable / oral dispersible or effervescent tablets. 
Isomalt can be used as a filler binder in tablets (56). Sugar alcohols are also known as common 
excipients for hard coating (57). Hard Coating is the traditional method of coating tablets. It is 
mainly used to mask unpleasant odors and tastes or to protect actives against light. Maltitol 
powder successfully replaces traditionally used sugars, and achieving faster coating. A pleasant 
cooling effect will be produced as some sugar alcohols dissolve. This unique effect is known as 
the “heat of solution” and is an actual exchange in energy. It can either lower or raise the 
temperature of a solution when a substance (sugar) is added to water (or saliva). As the heat of 
solution decreases into negative values, the cooling effect is more intense. Xylitol has been 
popular for its negative heat of solution which is more pronounced than that of other sugar 
alcohols, since they produce an intense cooling effect as the crystalline material dissolves (Table 
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6-1). Xylitol’s combination of sweetness and cooling can create product appeal while helping to 
mask the undesirable taste of many pharmaceutical actives or excipients (58). Due to their 
properties such as taste, mouth feel, low calorie content, non-carcinogenicity, suitability for 
diabetics and low hygroscopicity, they offers several advantages when formulated into 
pharmaceutical dosage forms. 
The term ‘solid dispersion’ has been utilized to describe a family of dosage forms whereby the 
drug is dispersed in a biologically inert matrix, usually with the objective to enhance oral 
bioavailability. Furthermore, the carrier used has, again traditionally, been a water-soluble or 
water miscible polymer such as polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) or low 
molecular weight materials such as sugars. In solid dispersions, the amorphous drug has a lower 
thermodynamic barrier for dissolution together with a maximally reduced particle size. The sugar 
alcohols can also be used as carriers in solid dispersions, since it is known that glass formation is 
common in many polyhydroxy substances, presumably due to their strong hydrogen bonding 
which may prevent recrystallization of the amorphous form of drug molecules. Furthermore, they 
possess the advantage of high thermal stability and absence of browning reactions. The studied 
sugar alcohols Mannitol, Sorbitol, and Xylitol are used in the manufacture of sugar-free hard 
candies and dietetic food.  
There are a variety of approaches to prepare solid dispersions, such as hot-melt extrusion (HME), 
spray drying, and solvent co-precipitation. Hot-melt extrusion is a solvent free process. Thus 
there are no concerns with solvent handling or recovery after processing. Also, there are no 
requirements on the compressibility of the active ingredients. The intense mixing and agitation 
by the extruder screw during processing causes suspended drug particles to disaggregate in the 
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polymer melt, resulting in a uniform dispersion of fine particles. Drug bioavailability may 
therefore be improved by dispersion of the drug substance at the molecular level in melt extruded 
dosage forms. During the HME extrusion process, a blend of the active ingredients, the 
thermoplastic polymers, and other processing aids is fed into the barrel of the extruder through 
the hopper. The materials are transferred inside the heated barrel by a rotating screw. 
Temperatures at different zones are controlled by several thermocouples in the barrel. The 
materials melt at elevated temperatures and the molten mass is continuously pumped through the 
die attached at the end of the barrel. The formulations are subject to heat only a few minutes 
within the extruder.  
Carbamazepine (CBZ) is an important anti-epileptic agent that has been in use for over 30 years. 
It is an example of a water-insoluble drug that requires relatively high dosing has a high dose 
requirement (>100 mg/day) to attain a therapeutic effect (59). The aqueous solubility of 
carbamazepine at 37 ºC was determined to be 237.2 ± 5.2 μg/mL and log P value of 2.3. CBZ 
poses multiple challenges for oral drug delivery, including a narrow therapeutic window, auto 
induction of metabolism and dissolution-limited bioavailability. CBZ crystallizes in at least four 
anhydrous polymorphic modifications (Table 6-4) with the energy separation is <0.7 kcal/mol 
between the most and least stable form and has been shown to form several solvates; including a 
stable dihydrate from aqueous solutions (60). The marketed formulations such as Tegretol
®
 
contain the pharmaceutically acceptable P-monoclinic or form III (60-61).  
Several attempts have been made by pharmaceutical scientists to improve dissolution profile of 
CBZ, by using water soluble carriers like polyvinyl pyrrolidone (PVP), polyethylene glycols 
(PEG) and Hydroxy propyl methyl cellulose (HPMC) (62) to prepare solid dispersions of CBZ, 
by preparing co-crystals with saccharin (63) or by using mesoporous silica as carriers (59).
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However, the preparation method of the solid dispersions or other more water soluble 
formulations studied in the literature involves organic solvents such as that used in freeze drying 
or involved with many discontinuous steps that are difficult to be successfully adopted by 
industry. HME is a continuous process that requires less offline testing. Melt extrusion requires 
fewer operator interventions and, thus, can yield improved product quality. This technology has 
become easier for industry to embrace due to the technical developments of recent years (i.e., 
extruder vendors have begun to produce units designed according to the principles of good 
manufacturing practice). The present study focuses on the formulation and processing of CBZ 
utilizing sugar alcohols (Mannitol, Sorbitol, and Xylitol) as HME produced matrices (Figure 6-
1). Furthermore, this manuscript proposes solutions for major issues in the development of solid 
dispersions by industry, such as process adaptability. This novel work demonstrates the utility of 
sugar alcohols for pharmaceutical dosage forms utilizing HME. The formulations studied were 
prepared by hot melt extrusion and characterized by differential scanning calorimetry (DSC), 
powder X-ray diffraction (PXRD) and in vitro release studies. 
6.3. MATERIALS 
Pearlitol
®
PF (Mannitol), Neosorb
®
 PF (Sorbitol), and Xylisorb
®
PF (Xylitol) were kindly gifted 
by Roquette Pharma, RCS Bethune, and France. All the excipients used were of pharmaceutical 
grade. Crystalline anhydrous Carbamazepine (CBZ) was obtained from Sigma Chemical Co. (St. 
Louis, MO). Other reagents (HPLC grade) were purchased from Fisher Chemicals, NJ. 
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6.4. METHODS 
6.4.1. HOT MELT EXTRUSION PROCESSING 
Carbamazepine (CBZ) was blended with the sugar alcohols (Mannitol, Sorbitol, and Xylitol) in 
two ratios, (1:10, and 1:4) in a V-cone blender for 10 minutes and analyzed for pre- and post-
extrusion content uniformity. Rod shaped hot melt extruded (HME) formulations were obtained 
using a Thermo Scientific HAAKE MiniLab at an extrusion temperature range of 120-175 °C 
(Mannitol formulations) and 80-100 °C (Sorbitol and Xylitol formulations) and processed at a 
screw speed of 75 rpm. The system is based on a conical, twin-screw compounder equipped with 
co rotating screws. The extrudates were pulverized using a sieve mesh size “22” according to US 
ASTM standards in a comminuting mill (FITZPATRICK, Model “L1A”). 
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Figure 6-1: Structures of sugar alcohols studied. 
6.4.2. THERMOGRAVIMETRIC ANALYSIS (TGA) 
A Perkin-Elmer Pyris-1 TGA (Shelton, CT) was used to determine the thermal stability of the 
sugar alcohols and CBZ. The samples were heated from 25 to 200 
°
C at a heating rate of 20 
 
C/min. All TGA runs were performed in an open pan with purge and protective nitrogen gas 
flow at 40 mL/min. 
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6.4.3. DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
The DSC thermograms were recorded using a Pyris 1 Perkin-Elmer Diamond DSC equipped 
with Pyris -7 Manager Software (Shelton, CT). DSC was used to study the crystallinity and 
solid-state physical stability of the HME formulations pre- and post-extrusion. Accurately 
weighed amounts (5-10 mg) of either the physical mixtures or the extrudates of sugar alcohols 
and CBZ were hermetically sealed in a flat-bottomed aluminum pan and heated from 25 
 
C to 
200 
 
C at a linear heating rate of 10 
 
C/min. The pure CBZ samples were tested at three different 
heating rates 10, 40 and 100 
°
C/min. An empty pan was used as a reference and calibrations for 
temperature and enthalpy were performed with indium. Measurements were repeated (n=3) and 
mean values with the respective standard deviation were determined. 
6.4.4. POWDER X-RAY DIFFRACTION (PXRD) 
The crystalinity of the drug was analyzed using PXRD. The samples were analyzed using a D-8 
Advance X-Ray Diffractometer (Bruker AXS, Madison, WI) equipped with a Sol X detector and 
Diffrac Plus software. The generator voltage and current was 40 kV and 40 mA, respectively. 
The 2 Theta scanning range was from 5º to 50º. The step size was 0.02º, and the dwell time at 
each step was 1 second. 
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6.4.5. FOURIER TRANSFORM INFRARED (FTIR) SPECTROSCOPIC ANALYSIS 
FTIR studied were done to detect the possible interactions between the CBZ and sugar alcohols 
in the solid dispersions leading to stabilization of amorphous state of CBZ. The FTIR spectra 
CBZ corresponded with those previously reported for Form III in the literature. The spectra were 
analyzed for the absence or shift in the wave numbers of the characteristic peaks and reported. 
6.4.6. IN VITRO EVALUATION 
Two-hundred milligrams of the pulverized extrudates were filled into size ‘0’ capsules. Hence, 
the formulations with CBZ and sugar alcohols (Mannitol, Sorbitol, and Xylitol) in the two ratios 
of 1:10 (CBZ equivalent to 20 mg) and 1:4 (CBZ equivalent to 50 mg) were used for analysis. 
The capsules were used to evaluate in vitro release, using a Type 2 apparatus (paddles) 0.5% 
SLS 900 ml as the dissolution medium at 37 ºC and the paddle rotation speed was 75 rpm with a 
Hanson SR8-Plus dissolution test system (Chatsworth, CA). Samples were collected at 
predetermined time intervals at 5, 15, 30, 45, 60, 90, and 120 min., filtered using 0.2 micron 
dissolution filter tips attached to a 1 ml nylon syringe, and analyzed by HPLC. All of the results 
are reported as the average of 3 replicates ± SD. 
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6.4.7. CALCULATION OF HANSEN SOLUBILITY PARAMETER 
The cohesive energy of a material is the energy that holds that substance together or the amount 
of energy required to separate the constituent atoms or molecules of the material. Cohesive 
energies are especially important to the pharmaceutical materials scientist since he/she determine 
many of the critical physico-chemical properties (e.g. solubility, melting point) of drugs and 
excipients. 
The cohesive energy of a material can be quantified in a number of ways. The most common 
approach is to use the solubility parameter (or cohesive energy densities (CED)). The solubility 
parameter of each component is defined as the square root of its CED, measured as the energy of 
vaporization per unit volume: 
δ = (CED) 1/2 = (∆Ev/Vm)
 1/2   
(6-1) 
The difference between the solubility parameters (δt) of two materials provides an estimation of 
the likelihood that they will be miscible 
21. The solubility parameter (δt) is calculated using the 
equation below. 
δt = √δd 
2
 + δp 
2
 + δh 
2
   (6-2)
 
The partial solubility parameters δd, δp and δh are calculated using group contributions for 
London dispersion forces, polar forces, and hydrogen bonding forces. 
6.4.8. STABILITY STUDIES 
The sample of each of the solid dispersions were transferred to HDPE bottles and placed inside 
humidity chambers pre-equilibrated to 25 ºC/60% RH and 45 ºC/75% RH. At specific time 
intervals during the course of the 6 month study, the HDPE bottles assigned for each time point 
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would be removed. The solid dispersions of CBZ with sugar alcohols were characterized using in 
vitro release studies. 
6.4.9. DATA ANALYSIS 
In all the cases, statistical analysis was performed utilizing one-way analysis of variance. A 
statistically significant difference was considered when p<0.05. 
6.5. RESULTS AND DISCUSSION 
6.5.1. HOT MELT EXTRUSION PROCESSING 
Xylitol exhibited best flow properties compared to other sugar alcohols. Mannitol and Sorbitol 
resulted in very viscous melts within the extruder demonstrating high die pressure and torque 
values. However, the intimate mixing of sugars and CBZ during the extrusion process resulted in 
homogenous extrudates for all of the formulations tested (CBZ assay > 100%). 
Sorbitol (Tm = 95 °C) is the stereoisomer of Mannitol. It is more hygroscopic compared to the 
other two sugars, as well as exhibiting less desirable melt flow properties. These properties were 
problematic for handling sorbitol during the extrusion process. Mannitol has a very high melting 
point (Tm = 165-167 °C). The requirement of processing conditions (above 165-170 °C) could 
be problematic for certain drugs. Xylitol (Tm = 98.5 °C) possesses better flow properties and 
exhibited good extrudability in comparison to Mannitol and Sorbitol (Table.6-2). 
Table 6-1: Comparison of heat of solution of selected sugar alcohols (64).  
Sugar Alcohols 
(Carriers) 
Heat of Solution 
(kJ/kg) 
Sorbitol -106.3 
Mannitol -120.9 
Xylitol -157.1 
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Table 6-2: Thermal properties of sugar alcohols (65). 
Sugar Alcohols 
(Carriers) 
Melting point (Tm) / 
Glass transition 
temperature (Tg) (ºC) 
Sorbitol 85-87/0 
Mannitol 160/10.7 
Xylitol 95/N.A 
 
Table 6-3: Hilderband total solubility parameter δt (H) between sugar alcohols and CBZ (66). 
 
Compound ∆δt (H)* ∆δ 
Carbamazepine 28.1 0 
Xylitol 37.1 9 
Sorbitol 38.2 10.1 
Mannitol 39.1 11 
*The ∆δ t values are from the referenced literature. 
Table 6-4: Transition Temperatures of the Four Polymorphs of CBZ (60).  
  
Triclinic 
Form I 
Trigonal 
Form II 
P-Monoclinic 
Form III 
C-Monoclinic 
Form IV 
Peak 1 (ºC) - 140-160 174.8 187.7 
Peak 2 (ºC) 193.5 192.1 193.2 191.5 
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6.5.2. CBZ-MISCIBILITY BY SOLUBILITY PARAMETERS 
BCS Class II drugs typically have solubility parameters of between 20 and 30 MPa
1/2
(26). It has 
been reported that systems with a ∆δt ranging from 1.6 to 7.5 MPa
1/2
 may show complete 
miscibility when in a molten state, systems with a ∆δt from 7.4 to 15.0 MPa
1/2
 may demonstrate 
immiscibility in the liquid state, and systems with a ∆δt above 15.9 will most likely exhibit total 
immiscibility. When the difference in solubility parameters is between 7.4 to 15.0 MPa
1/2
 
prediction of glass solution formation is considered only after further experiments are performed 
with thermal analysis. If the solubility parameters are greater than 10 MPa
1/2 
apart, a partially 
crystalline or two phase amorphous product is formed (26). The carriers utilized in our studies 
demonstrated ∆δt > 9 (Table 6-3). 
Pharmaceutical scientists recognize that there are limitations to the miscibility predictions based 
solubility parameters (26). Many of the drugs possess several polar and hydrogen bonding 
groups within the molecule and are most likely capable of interacting with different materials in 
a number of different ways. The donor-acceptor capacity of hydrogen-bonding groups in drugs 
and carriers must be considered to maximize interaction between the two materials. One further 
consideration when using solubility parameters is that they may be modified with temperature. It 
is possible that different materials will have solubility parameters which change to varying 
degrees with a change in temperature, such as during the processing conditions utilized during 
hot melt extrusion. These differences may become significant at high temperatures and may play 
a role in high melting point drug/carrier systems. It may be possible that the processing 
conditions during melt extrusion such as high temperature and shear increase the miscibility of 
drug and carriers. 
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6.5.3. THERMAL ANALYSIS 
Thermal gravimetric analysis (Figure 6-2) of sugar alcohols (Sorbitol, Mannitol, and Xylitol) and 
CBZ demonstrated thermal stability up to 200 °C. The different heating rates were utilized to 
confirm CBZ’s Form III defined within literature (Figure.6-3). The thermogram at 10 °C/ min 
demonstrated one endothermic peak occurred at 175.51 °C, followed immediately by an 
exotherm indicating melting of Form III and crystallization of Form I, respectively (Table. 6-4). 
A second endotherm corresponding to the melting of Form I appeared at 191.38 °C (60).  
The thermograms (Figure 6-4) indicate that the extruded formulations do not exhibit endotherms 
around the melting point of CBZ. The lack of CBZ melting endotherms in the HME solid 
dispersions suggests the presence of the drug in an amorphous form within the matrix. This can 
account for its higher release from the HME dispersions.  
The solid state characteristics of carrier sugars also play a role in release performance of solid 
dispersions. In thermograms, the melting endotherms of Sorbitol and Xylitol were not observed 
in melt extruded formulation systems (Figure 6-4 a and b). This would indicate the conversion of 
Sorbitol and Xylitol into an amorphous form. Mannitol based solid dispersions of CBZ can be 
classified as amorphous precipitation according to Table 1-2 i.e. drug is in amorphous form and 
carrier is crystalline. The amorphous state of the carriers markedly affects its usefulness as a 
carrier for formation of solid dispersions. An amorphous carrier in which the molecular 
arrangement is disordered helps penetration of dissolution media. 
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Figure 6-2: Thermal gravimetric analysis (TGA) of sugar alcohols and CBZ. 
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Figure 6-3: DSC thermogram of CBZ at different heating rates (deg /min). 
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Figure 6-4: DSC thermograms of formulations with Sorbitol and CBZ. 
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Figure 6-5: DSC thermograms of formulations with Mannitol and CBZ. 
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Figure 6-6: DSC thermograms of formulations with Xylitol and CBZ. 
 148 
6.5.5. PXRD 
PXRD is a powerful technique for the identification of crystalline solid phases. Every crystalline 
solid phase has a unique PXRD pattern, which can form the basis for its identification. CBZ’s 
characteristic high-intensity diffraction peaks were detected at: 2°θ-13.1, 15.4, 15.9, 17.2, 27.2 
and 27.5° matching CBZ Form III (62, 67). The PXRD patterns of all of the extruded 
formulations with sugar alcohols did not exhibit peaks corresponding to CBZ thus indicating that 
CBZ was in an amorphous form. The PXRD pattern of extrudates demonstrated absence of 
crystalline peaks in Sorbitol and Xylitol formulations, with the exception of Mannitol. These 
data corroborated the results from thermal analysis (Figures 6-7 to 6-9).  
 
Figure 6-7: Powder X-ray diffractogram of formulations with Sorbitol and CBZ. 
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Figure 6-8: Powder X-ray diffractogram of formulations with Mannitol and CBZ. 
 
Figure 6-9: Powder X-ray diffractogram of formulations with Xylitol and CBZ. 
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6.5.4. FOURIER TRANSFORM INFRARED SPECTROSCOPY 
FTIR studies were performed to detect the possible interactions between the CBZ and sugar 
alcohols in the solid dispersions leading to an amorphous state of CBZ. Figure 6-10 to 6-12 
shows the IR spectra of CBZ, sugar alcohols and their formulations. The characteristic bands of 
CBZ polymorph III were found at 3464.86, 3280.79 and 3157.17 cm
−1
 (–NH valence vibration), 
1675.77 cm
−1
 (–CO–R vibration), 1604.91 and 1594.38 cm−1 (range of –C=C– and –C=O 
vibration and –NH deformation). The FTIR spectra of CBZ corresponded with those previously 
reported for Form III in the literature (68). Sugar alcohols showed strong bands at 3200-3500 and 
1200-1500 cm
−1
 due to OH stretching (56-57). The physical mixtures of CBZ in ratios 1:4 and 
1:10 with Mannitol showed summation of CBZ and Mannitol IR spectra (Figure 6-12). However, 
in solid dispersions of CBZ in ratios 1:4 and 1:10 with Mannitol, the two bands approximately at 
3464 and 3280 cm
−1
 corresponding to the symmetrical and asymmetrical N–H stretching 
vibrations of primary amide groups of CBZ, seen in physical mixture, are replaced by a broader 
band at 3274 and 3278 cm
−1
, respectively, indicating the possible involvement of the –NH2 
group hydrogen bonding with OH groups of Mannitol. Sorbitol and Mannitol are isomers and 
hence have very similar IR spectra. In the case of Sorbitol and Xylitol based solid dispersions 
with CBZ in ratios 1:4 and 1:10 in addition to broader bands at 3280.79 cm
−1
 and 3157.17 cm
−1
 
(–NH valence vibration), they also exhibited shifts at 1675.77 cm−1 (–CO–R vibration), 1604.91 
and 1594.38 cm
−1
 (range of –C=C– and –C=O vibration and –NH deformation) indicating a 
second point of interaction (Figure 6-10 and 6-11). 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Sorbitol
Carbamazepine
Carbamazepine: Sorbitol 1: 10 Phy. Mix
Carbamazepine: Sorbitol 1: 10 extruded
3230.90
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1594.38
1488.94
1436.72
1381.69
1307.77
1245.73 1115.58
1040.40
981.00
870.16
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3279.93
2902.52
1677.04
1605.19 1488.97
1387.48
1301.16
1280.83
1078.10
1018.05
929.95
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3233.16
2932.40
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1414.89 1303.57
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1078.37
931.08
886.35
 
Figure 6-10: a) An overlay of FTIR spectra of Carbamazepine, Sorbitol, physical mixture (Phy. 
Mix) and extruded formulations in ratio 1:10. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Sorbitol
Carbamazepine
Carbamazepine: Sorbitol 1: 4 Phy. Mix
Carbamazepine: Sorbitol 1: 4 extruded
3464.86
3280.79
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1675.77
1604.91
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1115.58
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3465.33
3159.86
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1605.16
1594.78
1489.02
1384.01
1307.64
1246.41
1078.89
1018.80
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870.65
801.22 704.56
3233.04 2933.51
1655.16
1588.23
1412.58
1304.10
1252.00
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802.64
3230.90
2930.85
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1414.87
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1253.10
1086.83
938.31
884.49
870.88
 
Figure 6-10: b) An overlay of FTIR spectra of Carbamazepine, Sorbitol, physical mixture (Phy. 
Mix) and extruded formulations in ratio 1:4. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
CM-1
%T 
Mannitol
Carbamazepine
Carbamzepine: Mannitol 1:10 Phy. Mix
Carbamazepine : Mannitol 1:10 extruded
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1417.47
1300.45
1280.77
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3464.94
3354.79
3285.07
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2915.07
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1462.32
1436.43
1374.02
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1246.97
1111.25
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1004.92
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745.08
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1259.84
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Figure 6-11 a) An overlay of FTIR Spectra of Carbamazepine, Mannitol, physical mixture (Phy. 
Mix) and extruded formulations in ratio 1:10. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
CM-1
%T 
Mannitol
Carbamazepine
Carbamzepine: Mannitol 1:4 Phy. Mix
Carbamazepine : Mannitol 1:4 extruded
3279.50
2970.84
2902.71
1417.47
1300.45
1280.77
1209.11
1077.73
1018.08
958.87
929.13
879.82
784.28
694.00
3464.98
3281.00
2970.96
2902.99
1676.94
1605.26
1594.81
1488.99
1386.68
1301.54
1246.12
1208.60
1078.48
1018.63
959.08
929.28
879.75
801.22
763.22
696.34
3278.67
2938.22
1676.44
1372.16
1315.48
1260.18
1194.41
1077.27
950.68
926.80
3464.86
3280.79
3157.17
1675.77
1604.91
1594.38
1488.94
1436.72
1381.69
1307.77
1245.73 1115.58
1040.40
981.00
870.16
800.96
762.02
724.56
 
Figure 6-11 b) An overlay of FTIR Spectra of Carbamazepine, Mannitol, physical mixture (Phy. 
Mix) and extruded formulations in ratio 1:4. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Carbamazepine: Xylitol 1:10 extruded
Carbamazepine: Xytilol 1:10 Phy. Mix
Carbamazepine
Xylitol
3464.86
3280.79
3157.17
1675.77
1604.91
1594.38
1488.94
1462.24
1436.72
1381.69
3465.08
3159.57
2914.27
1677.26
1605.22
1594.83
1489.00
1383.55
1307.92
1247.14
3292.14
2934.30
1655.41
1407.43
1310.31 1216.01
3423.10
3359.23
3291.17
3152.83
2914.93
1418.95
1372.83
1351.55
1311.73
 
Figure 6-12: a) An overlay of FTIR Spectra of Carbamazepine, Xylitol, physical mixture (Phy. 
Mix) and extruded formulations in ratio 1:10. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Carbamazepine: Xylitol 1:4 extruded
Carbamazepine: Xylitol 1:4 Phy. Mix
Carbamazepine
Xylitol
3464.86
3280.79
3157.17
1675.77
1604.91
1594.38
1488.94
1462.24
1436.72
3465.20 3156.88
1676.74
1605.05
1594.65
1488.99
1462.41
1436.54
3292.37
2933.07
1663.94
1587.40
1400.21
3423.10
3359.23
3291.17
3152.83
2914.93
1418.95
1372.83
1311.73
 
Figure 6-12: b) An overlay of FTIR Spectra of Carbamazepine, Xylitol, physical mixture (Phy. 
Mix) and extruded formulations in ratio 1:4. 
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6.5.6. IN VITRO DRUG RELEASE PROPERTIES OF SOLID DISPERSIONS 
The dissolution media adopted by the pharmacopeias or recommended by FDA for in vitro drug 
release studies are designed to maximize drug release (69). Thus, the recommended medium for 
a given marketed drug becomes the quality control standard to ensure that batch-to-batch 
consistency and continuing product quality and performance are maintained regardless of 
changes in the manufacturing process.(70) The recommended media for in vitro dissolution 
testing can guide formulation development. It typically does not discriminate between 
formulation ingredients because a poorly soluble drug’s release is usually affected more by the 
medium than the formulation ingredients. Discriminatory dissolution profiles are highly 
desirable for distinguishing between products with different pharmaceutical attributes (e.g., 
formulation or manufacturing process differences) for poorly soluble drugs (70). There are some 
examples in the literature on selection of discriminatory dissolution medium for CBZ. Therefore, 
900 ml with 0.5 % SLS ml as the dissolution medium at 37 ºC, USP type II apparatus and the 
paddle rotation speed of 75 rpm was selected for study. 
Sugar alcohols (Mannitol, Sorbitol, and Xylitol) used in this investigation are readily soluble in 
an aqueous media. Upon exposure of these systems to an aqueous medium, the sugar rapidly 
dissolved and complete wetting of the drug occurred (64). During extrusion of sugars with CBZ 
mixtures, the crystalline form of the model drug, CBZ converted to its amorphous form, which is 
more water soluble. Also, the improvement in the dissolution rate of the drug in the presence of 
sugar alcohols can be attributed to a state of very fine subdivision attributed to agitation in the 
extruder. 
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FDA has set a public standard of f2 value of ‘50-100’ to indicate similarity between two 
dissolution profiles (71). Sorbitol formulations did not exhibit statistically significant different 
release rates at different drug loads (1:10 and 1:4). Mannitol and Xylitol formulations at the two 
different tested drug loads (1:10 and 1:4) were found to exhibit dissimilar release profile (f2 < 50, 
Figure 6-14 and 6-15). The release was decreased when CBZ concentration increased in the 
formulation. 
 
Figure 6-13: Release profile of formulations with Sorbitol in 0.5% SLS. 
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Figure 6-14: Release profile of formulations with Mannitol in 0.5% SLS. 
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Figure 6-15: Release profile of formulations with Xylitol in 0.5% SLS. 
6.5.7. STABILITY STUDIES 
The 6 month stability study data for extruded formulations with drug loads (1:10 and 1:4) was 
stable. The % CBZ content remaining in the pellet formulations was greater than 98.4%±0.4 and 
the drug release profile (f2>50) remained unchanged after 6 month storage at 40 °C/75% RH 
(Figure 6-16 to 6-18). The stability of the CBZ could be due to intermolecular interactions with 
sugar alcohols. 
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Figure 6-16: Release profiles of hot melt extruded formulations with Sorbitol at the initial, 1, 3 
and 6 month time points following storage at 40 °C/75%RH. 
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Figure 6-17: Release profiles of hot melt extruded formulations with Mannitol at the initial, 1, 3 
and 6 month time points following storage at 40 °C/75% RH. 
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Figure 6-18: Release profiles of hot melt extruded formulations with Xylitol at the initial, 1, 3 
and 6 month time points following storage at 40 °C/75%RH. 
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6.6. CONCLUSION 
The hot-melt extrusion process has been proven to be a promising technology for solubility 
enhancement of poorly water soluble drugs. The present study demonstrates the utility of HME 
as a method for solubility enhancement of CBZ (a class II BCS drug) using simple GRAS/ FDA 
approved excipients such as sugar alcohols. Traditionally, sugar alcohols have been utilized as 
bulking agents, taste-masking agents, and in cosmetic preparations. However, the solubilization 
potential of sugar alcohols remains largely un-explored. The sugar alcohols (Mannitol, Sorbitol, 
and Xylitol) investigated in this study proved to be very effective in forming solid dispersions for 
the BCS class II drug, CBZ. This novel study highlights both the utilization of HME as a 
process/technology and even more strikingly using sugar alcohols as solubilizers/ carriers to 
prepare solid dispersions of CBZ for the design of immediate release dosage forms.  
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CHAPTER - 7 
SUSTAINED RELEASE FROM EHTYL CELLULOSE PELLETS WITH LIPID 
BASED PROCESSING AIDS UTILIZING MELT EXTRUSION 
7.1. ABSTRACT 
The aim of this study was to investigate the efficiency of lipid based processing aids on an ethyl 
cellulose polymer in terms of their glass transition temperatures (Tg). Ethyl cellulose (EC) was 
plasticized with Stearic acid, Trimyristin and Tristearin at different concentration levels (10 to 
30% w/w). A significant decrease in Tg of the plasticized polymer was observed, which 
functioned as an indicator of plasticizing efficiency. The drug release rate was dependent on 
processing aid concentrations in all of the formulations for both of the model compounds, 
Chlorpheniramine Maleate (CLPM) and Diltiazem Hydrochloride (DTZ). All of the processing 
aid decreased the Tg of Ethocel
TM
, which facilitated the extrusion process. With addition of 
Stearic acid (10% w/w), the Tg of the EC matrix decreased from 132.6±2.5 °C to 125.4±1.7 °C. 
The pellets containing 10%w/w Stearic acid demonstrated desired sustained release profiles 
according to USP requirements for both model compounds with 45-51 % release in 6 to 8 hours 
in simulated intestinal fluid. Tristearin and Trimyristin at concentrations of 10%w/w also 
demonstrated desired release profiles. The drug release increased with an increase in 
concentration of lipid based processing aids from EC matrices. 
Keywords: Ethylcellulose, EC matrix, Lipid based processing aids, Stearic Acid, Tristearin, 
Trimyristin. 
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7.2. INTRODUCTION 
Ethocel
™
 (EC) polymers (ethylcellulose ethers) are a family of inert hydrophobic polymers that 
have been used as a coating material for tablets and granules, as a tablet binder, in the 
preparation of microcapsules and microspheres, and as a film/matrix forming material for 
controlled release formulations (33). Ethocel
™
 polymers are usually dissolved in an organic 
solvent during the preparation of the dosage form. Ethocel
™
 is a good candidate for extrusion as 
well because it exhibits thermoplastic behavior at temperatures above its glass transition 
temperature (Tg= 129–133 °C) (72). Typically, plasticizers are added to polymers to reduce their 
Tg and therefore permit processing at lower temperatures (73). 
Hot melt extrusion (HME) technology has recently gained significant importance in the 
pharmaceutical industry for the development of immediate and sustained release dosage forms 
(pellets, tablets) (1). Its advantages over conventional techniques for manufacturing of sustained 
release dosage forms (e.g. coating, compression) is the continuity of the extrusion technique as 
the different process steps (mixing, melting, homogenizing and shaping) are carried out on a 
single machine with no solvents necessary (74). Multi-particulate drug delivery systems are 
mainly oral dosage forms consisting of a multiplicity of small discrete units, each exhibiting 
some desired characteristics (75). In these systems, the dosage of the drug substances is divided 
on a plurality of subunit, typically consisting of thousands of spherical particles with diameter of 
0.05-2.00 mm (14). The objective of this project was to optimize the level of processing aids 
within EC matrices utilizing melt extrusion techniques for the sustained release (> 8 hours) of the 
model bioactives, Chlorpheniramine maleate (CLPM) and Diltiazem Hydrochloride (DTZ). 
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These model bioactives have high aqueous solubility of 160 mg/ml and 590 mg /ml at 25 °C, 
respectively (76-77). 
 
Figure 7-1: Structure of Ethocel
™
 (Ethylcellulose). 
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7.2. MATERIALS 
Trimyristin (Dynasan
®
 114) and tristearin (Dynasan
®
 118), monoacid triglycerides, were used in 
the powdered form as received from Sasol North America Inc. (Witten, Germany). 
Ethocel™ 7FP was kindly gifted by The Dow Chemical Company, Midland, MI. 
Chlorpheniramine Maleate and Stearic Acid were obtained from MP Biomedical, LLC (Solon, 
Ohio). Diltiazem Hydrochloride was purchased from Hawkins Inc., Minneapolis, MN. 
7.3. METHODS 
7.3.1. MANUFACTURE OF MELT EXTRUDED PELLETS 
EC was geometrically diluted and blended with CLPM and DTZ at 10 % w/w and 30 % w/w, 
respectively. The blends were manually fed through a hopper into an extruder (16 mm Prism 
Euro Lab, Thermo Fisher Scientific, Staffordshire UK).and processed at temperatures between 
110 and 150 °C. The screw speed was set to a 50 rpm, while torque remained below 50-60 
Newton, and the pressure was maintained at 60 PSI. The formulation strands were manually 
collected, and stored at 4 ºC. These strands were cut into pellets of 1 mm length using the 
pelletizer (Chapter 1, Figure 1-6) and filled in capsules. 
7.3.2. PLASTICIZATION EFFICIENCY: THERMAL ANALYSIS OF PHYSICAL 
MIXTURES 
DSC thermograms (n = 3) of samples were analyzed using a two step method: Initial heating step 
at 10 ºC/min. followed by cooling at 40 ºC/min. and a second heating at 10 ºC/min. after cooling 
the samples. EC was blended with Stearic acid, Trimyristin or Tristearin in 3 levels (10%, 20% 
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& 30% w/w) and analyzed using DSC for plasticization efficiency. EC blend with CLPM (10% 
w/w) and DTZ (30% w/w) with and without lipid based processing aids were also analyzed. 
7.3.3. DRUG-POLYMER BINDING STUDY 
A stock solution of DTZ and CLPM in phosphate buffer pH 6.8 (0.1 mg/ml) was prepared, and 
aliquots of 50 ml were filled into Erlenmeyer beakers. Increasing increments of EC (0, 10, 20, 
40, 60 mg) were added to the beakers, and the suspensions were incubated at 37 °C in an Innova 
4300 Incubator Shaker (New Brunswick Scientific Co., Edison, NJ) at 100 rpm. The sample of 
1ml were withdrawn, centrifuged, filtered, and analyzed for drug content after 24 hours. Analysis 
was performed in triplicate (78). 
7.3.4. FOURIER TRANSFORM INFRARED (FTIR) SPECTROSCOPIC ANALYSIS 
FTIR studied were done to detect the possible interactions between the EC and with Stearic acid, 
Trimyristin and Tristearin in the HME pellets. The spectra were analyzed for the absence or shift 
in the wave numbers of the characteristic peaks and reported. 
7.3.5. IN VITRO RELEASE STUDIES 
The pellets were weighed to 160 mg with formulations of CLPM and filled in size zero capsules. 
The pellets were weighed to 400 mg with formulations of DTZ and filled in size one capsules. 
These capsules were used for in vitro release studies, performed according to USP 31, using a 
type II apparatus. The dissolution medium consisted of 500 mL pH 6.8 (simulated intestinal 
fluid) and pH 1.2 (simulated gastric fluid) with temperature maintained at 37± 0.5 ºC. The paddle 
rotation speed was set at 100 rpm. At predetermined intervals, a 2.0 ml volume samples were 
removed and centrifuged using an accuSpin 
TM 
3R refrigerated benchtop centrifuge (Fisher 
Scientific, Pittsburgh, PA) at a speed of 10,000 rpm for 10 minutes at 37 ºC. The clear 
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supernatant was then transferred into vials and injected onto HPLC (Waters Corporation, 
Milford, MA) and analyzed for CLPM and DTZ. 
7.3.6. MODEL DRUG ASSAY 
The DTZ concentration in the dissolution medium at each sampled time point and formulations 
with EC were analyzed by means of HPLC (Waters Inc., Milford, MA). An aliquot of 20 μl was 
injected onto a C18-reversed phase column (Symmetry Shield C 18 4.6 X 250 mm, particle size 
5 µm) and analyzed at a flow rate of 1.0 ml/min using a mixture of phosphate buffer pH 4.0/ 
acetonitrile/ methanol in a 5:4:1 ratio as mobile phase. The drug content was measured at 237 nm 
with a UV/Visible detector (2489 Water, Waters Inc., Milford, MA), and peaks were integrated 
using Empower Version 2.0 software (Waters Inc.). 
The CLPM concentration in the dissolution medium at each sampled time point and formulations 
with EC were analyzed by means of HPLC (Waters Inc., Milford, MA). An aliquot of 20 μl was 
injected onto a C18-reversed phase column (Symmetry Shield C 18 4.6 X 250 mm, particle size 
5 µm) and analyzed at a flow rate of 1.0 ml/min using a mixture of phosphate buffer pH 4.2/ 
acetonitrile at a 3:7 ratio as mobile phase. The drug content was measured at 261 nm. 
7.3.7. STABILITY STUDIES 
The sample of each pellet formulation were transferred to HDPE bottles and placed inside 
humidity chambers pre-equilibrated to 25 ºC/60% RH and 45 ºC/75% RH. At specific time 
interval during the course of study 6 months, the HDPE bottles assigned for each time point 
would be removed. The pellet formulations were characterized using in vitro release studies. 
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7.3.7. DATA ANALYSIS 
In all the cases, statistical analysis was performed utilizing one-way analysis of variance. A 
statistically significant difference was considered when p<0.05. 
7.4. RESULT AND DISCUSSION 
7.4.1. PLASTICIZATION EFFICIENCY OF LIPID BASED PROCESSING AIDS ON EC 
Plasticizers are traditionally low molecular weight compounds that are added to polymers to 
modify their physico-mechanical properties. Plasticizer-polymer compatibility is defined as the 
ability of the plasticizer to form a homogeneous phase with the polymer without exudation 
(liquid plasticizers) or crystallization (solid-state plasticizers). The extent of Tg reduction in the 
presence of a plasticizer can be used as a parameter to assess the plasticization efficiency. The 
Tg of the EC was reduced from 133.5 ± 0.8 °C to 115.4 ± 2.8 °C at 30% w/w Stearic acid 
concentration (Figure 7-2). The EC matrix with 10 % w/w CLPM, the Tg was reduced to 110.3± 
1.3 °C. Trimyristin and Tristearin also demonstrated reduction in Tg of EC with and without 
CLPM. CLPM has been reported to act as processing aid in HME for HPC and Eudragit
®
 RSPO 
(79). In the case of EC matrices with 30% w/w DTZ, DTZ did not contribute in reduction of the 
Tg of EC (Figure 7 3). 
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Figure 7-2: Thermogram of second heating cycle of EC. The sample was heated from 25 to 200 
°C with a heating rate of 10 °C/min, cooled at 40 °C/min to -10 °C and then heated again 25 to 
200 °C with a heating rate of 10 °C/min. 
 
Figure 7-3: The effect of lipid based processing agents and CLPM on the Tg of EC. 
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Figure 7-4: The effect of lipid based processing agents and DTZ on the Tg of EC. 
7.4.2. DTZ AND CLPM BINDING TO EC 
Drug adsorption to the polymeric carrier may account for incomplete drug release from the 
matrix dosage forms. Within the literature, there has been a report of a complex formation 
between methacrylates and salts of acidic drugs in phosphate buffer solutions, which was mainly 
attributed to electrostatic interaction (78). In addition, non-electrostatic binding due to hydrogen 
bonding or van der Waals forces may lead to adsorption. This study results indicate (Figure 7-1) 
a statistically insignificant adsorption of DTZ on EC. CLPM demonstrated interaction potential 
with EC. 
 174 
 
Figure 7-5: Binding of DTZ and CLPM to EC. 
7.4.3 FTIR SPECTROSCOPY 
The spectrum of EC polymer in Figure 7-6 to 7-8 showed distinct absorption bands at 1052.70 
cm
−1
 for –C– O–C stretching vibration in cyclic ether and the asymmetric bands seen around 
2869 and 2973 cm
−1
 may be due to the C–H stretching (80). The band at 1052.70 cm−1 in pure 
EC and physical mixtures polymer shifted to lower wavenumbers 1030 to 1023 cm
−1 
in HME
 
pellets which is the indication of hydrogen bonding between them. This intermolecular 
interaction may be the reason in reduction of Tg of EC. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Ethyl Cellulose
Stearic Acid
Ethyl Cellulose with 10% Stearic Acid Phy. Mix
Ethyl Cellulose with 20% Stearic Acid Phy. Mix
Ethyl Cellulose with 30% Stearic Acid Phy. Mix
Ethyl cellulose with 10% Stearic Acid extruded
Ethyl Cellulose with Searic Acid 20% extruded
Ethyl Cellulose with Stearic Acid 30% extruded
3475.88
2973.41
2869.74
1443.63
1374.84 918.51
882.28
2954.13
2914.90
1698.57
1463.28
1429.82
1355.51
1313.31
1240.90
1186.47
1103.23
940.66
809.91
760.39
2973.44
2870.20
1699.01
1374.83
1052.48
918.84
882.20
2973.33
2868.36
1374.44
1051.71
918.29
881.78
2915.18
2848.29
1699.37
1471.97
1463.19
1374.10
1297.59
1240.83
1052.26
941.92
884.55
728.23
719.57
3330.42
2914.92 2847.66
1700.93 1471.87
1462.94
1429.01
1313.21
1259.99
1221.94
1103.56
1025.43
940.91
727.83
719.71
2954.26
2914.99
1700.43
1472.10
1411.61
1103.29
1031.84
941.17
809.93
760.26
728.20
3330.43
2954.00
1700.63
1472.02
1411.55
1355.82
1330.86
1279.13
1260.12
1103.18
1028.55
941.08
809.82
760.31
719.69
688.67
 
Figure 7-6: An overlay of FTIR spectra of Ethylcellulose, Stearic Acid and Ethylcellulose 
containing Stearic Acid 10-30 % w/w in physical mixtures (Phy. Mix) and extruded matrix. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Ethyl Cellulose
Ethyl Cellulose with 10%Tristearin Phy. Mix
Ethyl Cellulose with 20%Tristearin Phy. Mix
Ethyl Cellulose with 30%Tristearin Phy. Mix
Ethyl Cellulose with 10%Tristearin extruded
Ethyl Cellulose with 20%Tristearin extruded
Ethyl Cellulose with 30%Tristearin extruded
Tristearin
3475.88
2973.41
2869.74
1443.63
1374.84
1052.70
918.51
882.28
3305.63
2955.85
2914.40
2849.33 1730.11
1471.22
1418.36
1330.52
1243.57
1177.99
1101.00
1047.61
992.15
943.97
876.23
717.59
2972.12
2914.35
2849.62
1730.24
1471.35
1376.02
1309.63
1196.42
1100.05
1049.54
919.22
881.50
717.60
3475.63
2972.78
2915.09
2849.88 1730.65 1471.23 1375.56
1309.54
1196.98
1052.67
919.08
882.29
718.00
3390.67
2914.48 2849.44
1730.48
1471.55 1377.44
1310.07
1266.20
1177.48
1100.36
1029.42
878.23
717.51
3472.81 2914.73
2849.64
1730.46
1471.13 1376.40
1309.84
1266.36
1196.59
1176.90
1099.89
1049.15
920.41
881.58
717.88
3315.62 2914.30
2849.28 1730.26
1471.54 1378.09
1310.07
1287.75
1219.21
1178.91
1104.42
1027.22
944.03
877.87
717.27
3306.75
2956.89
2849.58 1730.28
1471.64
1392.02
1308.83 1100.19
1029.44
944.56 874.84
716.87
Figure 7-7: An overlay of FTIR spectra of Ethylcellulose, Tristearin and Ethylcellulose 
containing Stearic Acid 10-30 % w/w in physical mixtures (Phy. Mix) and extruded matrix. 
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4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Ethyl Cellulose
Trimyristin
Ethyl Cellulose with 10% Trimyristin Phy. Mix
Ethyl Cellulose with 20% Trimyristin Phy. Mix
Ethyl Cellulose with 30% Trimyristin Phy. Mix
Ethyl Cellulose with 10% Trimyristin extruded
Ethyl Cellulose with 20% Trimyristin extruded
Ethylcellulose with 30% Trimyristin extruded
3475.88
2973.41
2869.74
1443.63
1374.84
1052.70
918.51
882.28
3447.12
2955.89
2915.57 2848.87 1735.96
1465.48
1379.70
1189.89
1174.93
1110.11
1054.26
719.52
3462.75
2915.79
2849.05
1736.04
1465.48
1377.42 1270.10
1222.47
1173.38
1106.70
1054.31
882.29
719.58
3472.17
2915.46
2848.84
1735.64
1464.59
1376.36
1270.25
1222.32
1172.35 1053.98
882.62
719.31
3452.98
2915.82 2849.08
1736.24 1465.39
1378.25
1254.62 1108.47
1054.21
881.63
719.62
3417.17
2916.62
2849.48 1736.29 1464.03
1376.22
1270.62
1205.81
1028.64
921.43
882.47 719.33
3378.47
2916.31
2849.10
1736.00
1463.99
1379.34 1270.02
1175.33
1110.03
1028.65 719.27
3377.68
2849.08 1736.02 1464.02
1378.91
1254.59
1109.66
1028.74
719.30
Figure 7-8: An overlay of FTIR spectra of Ethylcellulose, Trimyristin and Ethylcellulose 
containing Trimyristin 10-30 % w/w in physical mixtures (Phy. Mix) and extruded matrix. 
7.4.1. RELEASE STUDIES 
Sustained release is an outcome of a dissolving drug having to diffuse through a network of 
channels that exist between compacted polymer particles (81). The drug release rate and 
mechanisms from matrix-type delivery systems are influenced by a multitude of factors. These 
include matrix porosity, permeability, swelling behavior and solubility of the polymer, load of 
soluble compounds in the formulation, drug solubility, drug solid-state and particle size, 
plasticizer type and level and dosage form geometry and surface area (82). The drug release from 
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insoluble carrier materials including polymers and lipids is mainly governed by diffusion, which 
can be understood as a three-step process:  
1. Water ingression into the matrix,  
2. Drug dissolution and  
3. Drug diffusion through the matrix into the dissolution medium.  
Each of the steps can be rate controlling, depending on the properties of the matrix. If the 
polymer swells or dissolves in the dissolution medium, further release mechanisms come into 
play. Generally, in matrix systems, there are two major factors that control the rate of release of 
the drug from the matrix. One is the rate of aqueous medium infiltration into the matrix 
followed by a relaxation process (hydration, gelation or swelling) and the other is the rate of 
erosion of the matrix (83). As a result of these simultaneous processes, two fronts are evident, a 
swelling front (glassy polymer / gel interface) and an eroding front (gel /medium interface). The 
distance between the two fronts (diffusion layer thickness) depends on the relative rates at 
which the swelling and eroding fronts move in relation to each other. Various mathematical 
equations were used to evaluate drug release mechanisms from the formulations tested (Figure 
7-4 -7-9). The zero order Equation 7-1, describes systems in which the drug release rate is 
independent of its concentration. The first order Equation 7-2 describes the release from 
systems where release rate is concentration dependent. The release of drugs from an insoluble 
matrix can be described as a square root of time dependent process based on Fickian diffusion, 
Equation (7-3). The mechanism of drug release from matrices containing swellable polymers is 
complex and not completely understood. Some systems may be classified as either purely 
diffusion or erosion controlled, while most systems exhibit a combination of these mechanisms 
(84).  
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Qt = Q0 + K0t     Equation 7-1 
ln Qt = ln Q0 – k1.t    Equation 7-2 
Qt = K.S √t = kH .√t    Equation 7-3 
The Korsmeyer–Peppas model is used to analyze drug release from pharmaceutical dosage forms 
when the release mechanism is not well known or when more than one type of release 
phenomena is involved. The exponent, termed the release exponent or n value, was studied to 
characterize different drug release mechanisms (83).  
CLPM release kinetics from the pellets 
The release profiles of all the formulations in both pH buffers were plotted according to various 
release kinetic models and correlation coefficient values (r
2
) are listed in Table 7-3 and 7-4. The 
model demonstrating the highest value of r
2
 was selected as best fit to explain drug release 
mechanisms. The formulation with Stearic acid (10% w/w) followed zero order release kinetics. 
With the increase in concentration of Stearic acid (20-30% w/w), the release profile seem to best 
fit the first order release kinetics. In 6 hours, 35-45% CLPM and after 10 hours more than 80% 
CLPM release was observed with pellet formulation in simulated intestinal fluid and simulated 
gastric fluid with 10%w/w processing aids. In summary, for the lipid processing aids (Stearic 
acid, Tristearin and Trimyristin), the 10%w/w levels incorporated in Ethocel
TM 
matrices 
exhibited desired release profiles according to USP requirements for CLPM extended release 
capsules (Table 7-1). Therefore, for designing successful sustained release of CLPM, the 
optimum concentration of Stearic acid would be 10% w/w (Figure 7 10a to7 15a). The systems 
with Trimyristin (10-30% w/w) followed first order release and the Higuchi model in pH 6.8 
(simulated intestinal fluid) and pH 1.2 (simulated gastric fluid). The Higuchi model describes the 
diffusion of drug from an insoluble matrix. This may indicate diffusion of drug from the EC 
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matrix is dependent on the concentration gradient. The drug release from the matrix was the 
result of penetration of dissolution medium through pores or channels and leaching out of the 
drug. Hence, Trimyristin created these pores or channels and facilitated the drug release. The 
systems with Tristearin (10–30% w/w) also followed first order release kinetics.  
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DTZ release kinetics from the pellets 
The model demonstrating the highest value of r
2
 in Table 7-5 and 7-6 was selected as best fit to 
explain DTZ release mechanism from all of the formulations. It is observed that DTZ release 
kinetics from the matrix demonstrates the combination of mechanism is has the highest value of 
r
2 
when fitted to the first order release model. With the increase in concentration of processing 
aids (20-30% w/w), the release profile demonstrated the highest r
2 
(0.998-0.997) value when 
fitted to Higuchi model. The release was combination of Higuchi and First order model, which 
indicates the diffusion and erosion of the matrix. In 3 hours, 35-45% DTZ and after 8 hours more 
than 80% DTZ release was observed with pellet formulation in simulated intestinal fluid and 
simulated gastric fluid with 10%w/w processing aids (Figure 7 10 b to7 15 b) . In summary, for 
the lipid processing aids (Stearic acid, Tristearin and Trimyristin), the 10%w/w levels 
incorporated in Ethocel
TM 
matrices exhibited desired release profiles according to USP 
requirements for DTZ extended release capsules (Table 7-2). 
Table 7-1: USP requirements for CLPM extended release capsule formulation. 
Time (Hours) Amount Dissolved 
1.5 Between 15 % and 40 % 
6 Between 50 % and 80 % 
10 Not less than 70 % 
 
Table 7-2: USP requirements for DTZ extended release capsule formulation. 
Time (Hours) Amount Dissolved 
1 Not more than 15 % 
3 Between 45 % and 70 % 
8 Not less than 80 % 
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Table 7.3: Dissolution kinetics of pellets with CLPM 10 % w/w in EC matrix in pH 6.8 buffer. 
Formulations 
Zero 
order 
First 
Order 
Higuchi 
Model 
Peppas–
Korsmeyer 
r
2
 r
2
 r
2
 r
2
 n 
Stearic Acid 
10% 0.998 0.989 0.947 0.962 1.250 
20% 0.991 0.994 0.978 0.987 0.124 
30% 0.949 0.984 0.984 0.949 0.323 
Trimyristin 
10% 0.988 0.995 0.984 0.994 0.171 
20% 0.964 0.987 0.994 0.969 0.291 
30% 0.952 0.983 0.992 0.966 0.347 
Tristearin 
10% 0.971 0.998 0.993 0.986 0.210 
20% 0.946 0.999 0.996 0.983 0.342 
30% 0.943 0.985 0.995 0.973 0.392 
Table 7-4: Dissolution kinetics of pellets with CLPM 10 % w/w in EC matrix in pH 1.2 buffer. 
Formulations 
Zero 
order 
First 
Order 
Higuchi 
Model 
Peppas–
Korsmeyer 
r
2
 r
2
 r
2
 r
2
 n 
Stearic Acid 
10% 0.992 0.979 0.973 0.962 0.082 
20% 0.986 0.996 0.986 0.991 0.211 
30% 0.937 0.993 0.995 0.976 0.445 
Trimyristin 
10% 0.936 0.995 0.993 0.967 0.281 
20% 0.918 0.994 0.988 0.956 0.352 
30% 0.884 0.997 0.980 0.954 0.528 
Tristearin 
10% 0.936 0.996 0.997 0.993 0.384 
20% 0.963 0.915 0.994 0.969 0.417 
30% 0.883 0.972 0.979 0.947 0.536 
 
 183 
Table 7-5: Dissolution kinetics of pellets with DTZ 10 % w/w in EC matrix in pH 6.8 buffer. 
Formulations 
Zero 
order 
First 
Order 
Higuchi 
Model 
Peppas–
Korsmeyer 
r
2
 r
2
 r
2
 r
2
 n 
Stearic Acid 
10% 0.975 0.993 0.981 0.985 0.123 
20% 0.966 0.997 0.998 0.989 0.270 
30% 0.945 0.992 0.992 0.973 0.372 
Trimyristin 
10% 0.989 0.999 0.984 0.993 0.204 
20% 0.952 0.987 0.986 0.944 0.338 
30% 0.955 0.982 0.995 0.979 0.379 
Tristearin 
10% 0.965 0.999 0.996 0.996 0.259 
20% 0.961 0.997 0.997 0.973 0.300 
30% 0.935 0.998 0.993 0.993 0.403 
Table 7-6: Dissolution kinetics of pellets with DTZ 10 % w/w in EC matrix in pH 1.2 buffer. 
Formulations 
Zero 
order 
First 
Order 
Higuchi 
Model 
Peppas–
Korsmeyer 
r
2
 r
2
 r
2
 r
2
 n 
Stearic Acid 
10% 0.979 0.995 0.978 0.974 0.121 
20% 0.954 0.995 0.996 0.961 0.306 
30% 0.955 0.992 0.993 0.968 0.375 
Trimyristin 
10% 0.991 0.997 0.981 0.964 0.195 
20% 0.965 0.992 0.991 0.971 0.335 
30% 0.955 0.979 0.995 0.991 0.390 
Tristearin 
10% 0.951 0.995 0.996 0.969 0.336 
20% 0.928 0.998 0.994 0.982 0.435 
30% 0.912 0.974 0.989 0.967 0.551 
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Figure 7-9 a: Release profiles of CLPM from EC pellets with Stearic acid in pH 1.2 buffer. 
 
 
Figure 7-9 b: Release profiles of DTZ from EC pellets with Stearic acid in pH 1.2 buffer. 
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Figure 7-10 a: Release profiles of CLPM from EC pellets with Trymyristin in pH 1.2 buffer. 
 
Figure 7-10 b: Release profiles of DTZ from EC pellets with Trymyristin in pH 1.2 buffer. 
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Figure 7-11 a: Release profiles of CLPM from EC pellets with Tristearin in pH 1.2 buffer. 
 
Figure 7-11 b: Release profiles of DTZ from EC pellets with Tristearin in pH 1.2 buffer. 
 187 
 
Figure 7-12 a: Release profiles of CLPM from EC pellets with Stearic acid in pH 6.8 buffer. 
 
Figure 7-12 b: Release profiles of DTZ from EC pellets with Stearic acid in pH 6.8 buffer. 
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Figure 7-13 a: Release profiles of CLPM from EC pellets with Trimyristin in pH 6.8 buffer. 
 
 
Figure 7-13 b: Release profiles of DTZ from EC pellets with Trimyristin in pH 6.8 buffer. 
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Figure 7-14 a: Release profiles of CLPM from EC pellets with Tristearin in pH 6.8 buffer. 
 
 
Figure 7-14 b: Release profiles of DTZ from EC pellets with Tristearin in pH 6.8 buffer. 
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7.5. CONCLUSION 
Sustained release matrix pellets could be successfully prepared by hot-melt extrusion when 
plasticized EC was employed as the matrix material. Lipid based processing aids efficiently 
lowered the required processing temperatures, by reducing Tg of EC and melt viscosity. Stearic 
acid demonstrated superior plasticization efficiency. Trimyristin and Tristearate were 
investigated for the first time as processing aids. With 10% w/w incorporated into EC matrices, 
the desired release profiles of the model drugs were achieved. With addition of Stearic acid (10% 
w/w), the Tg of the EC matrix decreased from 132.6±2.5 °C to 125.4±1.7 °C. The pellets 
containing 10% w/w Stearic acid demonstrated desired sustained release profiles according to 
USP requirements for both model compounds with 45-51% release in 6 to 8 hours in simulated 
intestinal fluid. Tristearin and Trimyristin at concentrations of 10% w/w also demonstrated 
desired release profiles. The drug release increased with an increase in concentration of lipid 
based processing aids from EC matrices. CLPM also reduced the Tg of EC whereas DTZ did not 
exhibit a significant effect on the Tg of polymeric matrix. The present study demonstrated 
utilization of HME as viable technique for development of sustained or extended release 
formulations utilizing lipid based processing aids plasticized EC matrices. 
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